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 Breast cancer metastasis is a complex process, promoted by a variety of cell types 
including cancerous mammary epithelial cells and stromal cells including fibroblasts, T 
cells and tumor associated macrophages (TAMs), which can make up 50% of tumor mass 
in late-stage, primary breast tumors. TAMs promote tumor growth, angiogenesis and 
metastasis through the release of inflammatory chemokines, growth factors and proteolytic 
enzymes including the cysteine cathepsins B, L, K, S and V. Macrophage secretion of these 
proteases and the endogenous cathepsin inhibitor, cystatin C, differs significantly between 
individuals, contributing to variability in patient outcomes and response to treatment. 
Cathepsins are potent catalysts of extracellular matrix (ECM) degradation, but have also 
been identified as regulators of cellular process that operate through the activation of 
signaling pathways and the cleavage of transmembrane receptor proteins, chemokines, and 
cellular adhesion molecules. 
 Cysteine cathepsins are components of a complicated regulatory proteolytic 
network, which includes multiple biochemical and biomechanical stimuli, endogenous 
protease inhibitors, and other proteases capable of activating or degrading other proteases 
while degrading substrates and inhibitors simultaneously. Cysteine cathepsins which 
include the most powerful mammalian collagenase and elastase, have become attractive 
pharmaceutical targets, motivating billions of dollars in research by pharmaceutical 
companies for a number of tissue destructive diseases. Despite the development of highly 
specific, tight binding inhibitors that have shown clinical efficacy in treating the target 
disease, no cathepsin inhibitor has yet received FDA approval due to the emergence of 
unexpected side effects in trial participants. 
 xix 
 While cathepsins were once thought to be restricted to bulk protein turnover in 
lysosomes, researchers have begun to uncover the diverse tissue distribution, function and 
regulation of cathepsins both in healthy systems and in an ever-growing array of 
pathologies. Unraveling the complicated proteolytic web of interactions between enzymes, 
substrates and inhibitors will be critical to the development of cathepsin inhibitor 
treatments capable of suppressing cancer metastasis and other related diseases. Studying 
these mechanisms exclusively with experimental methods has been difficult, due to 
technological limitations, rapid reactions kinetics, promiscuity of proteases with substrates 
and the undetermined number of interactions and associated variables in these regulatory 
networks. This work combines experimental and computational methods to explore the 
effects of cathepsin inhibitors on intracellular and extracellular cathepsin dynamics in 
breast cancer. 
 Treating breast cancer cells with a cathepsin inhibitor has been shown to actually 
increase active cathepsins in those cells. We have since found this unexpected inhibitor 
response in macrophages and primary human tissue, which displays a great deal of person-
to-person variability in endogenous active proteases and response to protease inhibitor 
treatment. This dissertation details the development of a mechanistic mathematical model, 
which revealed that this differential response to inhibitor treatment is driven by differences 
in intracellular environment and intrinsic properties of the enzymes. This model was also 
adapted to explore hypotheses about intracellular trafficking of cathepsin inhibitors and the 
impacts different classes of inhibitors can have on the same cellular cathepsin system that 
may be contributing causes to the unexplained side effects plaguing the pharmaceutical 
industry. 
 xx 
 In addition to degrading the extracellular matrix and other protein substrates, some 
members of the cathepsin family have been shown to degrade other cathepsins, even in the 
presence of other substrates, a phenomenon known as “cathepsin cannibalism”. This 
phenomenon was discovered using recombinant enzymes in vitro. In this work we have 
shown that cathepsin cannibalism can occur in cellular systems and produced a series of 
dynamic mathematical models to predict how these cathepsin-on-cathepsin interactions 
affect cathepsin levels and overall proteolysis in living cells. Cathepsin cannibalism could 
have a significant effect on systems where multiple cathepsins coexist, particularly in the 
tumor microenvironment where multiple cathepsin family members contribute to 
extracellular matrix degradation, facilitating tumor metastasis. Effective inhibition of 
matrix proteolysis in these systems will require an understanding of cathepsin-on-cathepsin 
interactions, since the addition of a specific cathepsin inhibitor could result in unexpected 
side effects due to the disruption of cannibalistic regulation. 
 This dissertation details the challenges inherent to studying systems of interacting 
biological agents in complex cellular systems and takes a hybrid experimental and 
mathematical approach to exploring these interactions. The data and models generated by 
this work will be useful in the creation of new experimental and mathematical tools to 
study these complex regulatory networks and inform the development of new cathepsin 









1.1 Research Objectives and Specific Aims 
 The overall objective of this work was to develop experimental and mathematical 
tools capable of measuring and predicting proteolytic network dynamics in multicellular 
systems. The central hypothesis was that cathepsin inhibitors provoke unexpected side 
effects in cellular systems by disrupting cathepsin interactions with endogenous inhibitors, 
substrates and proteases.  
 
Aim 1: Develop and characterize experimental tools to probe regulatory interactions 
between cathepsins, substrates and inhibitors in breast cancer and macrophages. 
The hypothesis of this aim is that cathepsin profiles differ by cell type, resulting in cell-to-
cell and person-to-person variation in proteolytic regulatory networks. Cathepsins are 
challenging enzymes to study experimentally as they are tightly regulated due to their 
potency, requiring consideration of pro and mature forms, activation, oxidation, substrates, 
loss of activity and denaturation. Work that contributes to this aim includes the 
characterization of the proteolytic profiles of macrophages (Chapter 3), the validation of 
mRNA for cathepsin and inhibitor overexpression (Chapter 5) and the purification of 
recombinant cathepsins (Chapter 6). 
 
Aim 2: Predict multicellular active enzyme levels and generate hypotheses to identify 
unknown proteolytic network interactions using computational models. 
The hypothesis of this aim is that one cathepsin species can affect the activity and 
expression of another cathepsin species through activation, degradation and competition 
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for substrates and inhibitors. Computational modeling is a useful technique for studying 
the interactive networks of proteases, particularly the protease states that can be difficult 
to resolve experimentally including complexes of cathepsins with inhibitors, substrates or 
other proteases; denatured or inactive proteases; amounts of degraded enzymes and 
substrates as they are removed from the system. Work that contributes to this aim includes 
the creation of a multicellular model of cathepsin S and K interactions in engineered cells 
(Chapter 4) and the development of a dynamic model of inhibitor induced increases in 
active cathepsins in breast cancer cells (Chapter 7). 
1.2 Significance of Results 
 This work is innovative because it applies a hybrid computational and experimental 
approach to study a complex regulatory network that contributes to unexpected side effects 
of cathepsin inhibitor treatment in patients suffering from tissue destructive diseases that 
are cathepsin-mediated. Further, this work applies mechanisms previously documented in 
vitro and confirms their existence in cellular systems and generates tools enabling 
predictions of cathepsin dynamics in cellular systems. The long-term goal of this project is 
to define unknown regulatory functions of cathepsins, that when perturbed by inhibitors, 
provoke unexpected side effects that reduce their chances of being used clinically. 
Understanding these proteolytic network interactions will inform the design of new 







2.1 Breast cancer and tumor associated macrophages 
2.1.1 Cancer metastasis and the tumor microenvironment 
 Breast cancer is the most common cancer among women and the second most 
deadly cancer in women [1]. Metastatic spread of secondary tumors to vital organs such as 
the lungs, liver and bone marrow is responsible for most deaths due to breast cancer [2, 3]. 
Cancer growth and metastasis are complex processes promoted by a variety of stromal 
cells, including tumor associated macrophages (TAMs) and cancer associated fibroblasts 
(CAFs) [4]. Breast cancer is a highly heterogeneous disease, manifesting in differences in 
progression, metastasis and outcomes among patients. Differences in cancer subtype, 
defined by the presence or absence of progesterone receptors (PR+) estrogen receptors 
(ER+) and human epidermal growth factor receptor 2 (HER2+) on the cancer cells, also 
contribute to differences in metastatic potential [5]. This heterogeneity extends to the 
cellular level in a single patient, where individual cancer and stromal cells in the tumor 
microenvironment can have significantly different impacts on cancer growth and 
metastasis [6]. Unravelling this web of connections between cancer and stromal cells will 
be critical for developing safe, effective and personalized treatments for cancer metastasis. 
2.1.2 Tumor associated macrophages promote tumor growth and metastasis  
 Macrophages are the most abundant immune cells in mammary tumors and 
contribute to tumor development and metastasis by secreting inflammatory factors, 
remodeling the tumor microenvironment and degrading the extracellular matrix of the 
basement membrane [7-11]. TAMs facilitate tumor proliferation and angiogenesis through 
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continual extracellular matrix remodeling, while also suppressing adaptive immune 
responses targeted at tumor cells [12-14]. Macrophages and tumor cells secrete a variety 
of proteases including matrix metalloproteinases (MMPs), aspartyl proteases and cysteine 
cathepsins into the tumor microenvironment where they promote tumor angiogenesis 
through the cleavage of ECM into angiogenic growth factors, and allow tumor cells to enter 
the vasculature by compromising the basement membrane and degrading cellular adhesion 
molecules opening gaps for cancer cells to spread [8, 15].  
2.2 Cysteine cathepsins  
2.2.1 Cathepsins are highly regulated proteases 
 Cysteine cathepsins are potent degraders of extracellular matrix proteins involved 
in a host of pathologies including cancer, atherosclerosis and osteoporosis. There are 11 
cysteine cathepsins (B, C, F, H, K, L, V, O, S, W, X/Z) including the most potent known 
human elastase, cathepsin V, and collagenase, Cathepsin K [16-19]. Cathepsins are 
components of a complicated regulatory proteolytic network that includes multiple 
biomechanical and biomechanical pathways, endogenous protease inhibitors and other 
proteases capable of activating pro-proteases into their mature active forms, or binding and 
degrading pro or mature proteases [20-24]. Many of these enzymes are implicated in 
extracellular matrix remodeling, and recent research suggests they are also involved in 
regulatory processes including apoptosis, autophagy, protein activation and antigen 
presentation [16, 25-28]. Cysteine cathepsin activity is also regulated by pH and redox 
conditions, with the majority of cathepsins degrading substrate most effectively in low pH 
and mildly reducing environments similar to lysosomes, with the notable exception of 
cathepsin S, which retains its activity at neutral pH [29]. 
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2.2.2 Cathepsins promote cancer metastasis 
 Several cathepsins have been identified in tumor associated macrophages (B, C, K, 
L, S, V, X) and breast cancer cells (B, F, H, K, L, S, V, X) [25, 30]. Cathepsin K has been 
identified in both primary breast tumor sites as well as in bone metastatic sites [31]. 
Treatment with the pharmaceutical cathepsin K inhibitor odanacatib was found to 
significantly reduce metastatic bone disease in women with breast cancer compared to 
placebo [32]. Cathepsin V (also known as cathepsin L2) has been identified as an antigen 
using sera from patients with breast cancer [33]. Interestingly, while cathepsin L has been 
identified as a promoter of tumor growth, invasion and metastasis in breast cancer [34], 
loss of cathepsin L has been shown to promote intestinal neoplasia [35] and epidermal 
carcinoma [36]. Cathepsin B has a near ubiquitous tissue distribution, but it is 
overexpressed in many cancers including breast, cervix and prostate [37, 38]. 
Pharmacological inhibition of cathepsin B has been shown to decrease bone metastases in 
a mouse model of metastatic breast cancer [39]. Inhibition with a broad spectrum cysteine 
cathepsin inhibitor failed to suppress metastasis in a murine model of breast cancer, while 
a cathepsin B specific treatment significantly reduced secondary tumor volume in the spine 
and lung, suggesting some cathepsins may play anti-tumorigenic roles [39]. Cathepsins S 
and B produced by tumor associated macrophages have been shown to protect tumors from 
chemotherapy induced cell death in a murine model of breast cancer [40]. 
2.2.3 Pharmacological cathepsin inhibitors 
 Proteases have long been implicated in the development and metastasis of cancer. 
Several protease families of interest have been identified including matrix 
metalloproteinases (MMPs), and serine, aspartic and cysteine proteases. While gene 
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knockout, RNA interference and enzyme inhibitor treatments have shown efficacy in 
human in vitro and murine in vivo systems, successful implementation in human clinical 
trials has been curtailed by a variety of off-target effects including skin lesions and 
cardiovascular complications [41]. 
 Upregulation of cathepsins in pathologies including cancer, cardiovascular disease 
and osteoporosis have made these enzymes attractive targets for pharmaceutical inhibition 
[42-44]. Multiple potent, specific small molecule inhibitors of different cathepsins have 
been developed, but despite showing clinical efficacy in trials for osteoporosis and bone 
metastasis, to-date no cathepsin inhibitors have been cleared for clinical use for any 
pathology due to unexpected side effects [32, 41, 45, 46]. 
 Cathepsin inhibitors have a history of provoking unexpected results in vivo and in 
vitro [47, 48]. Healthy subjects treated with a specific cathepsin S inhibitor exhibited a 
dose-dependent increase in both total plasma cathepsin S and cathepsin S activity [49]. Our 
group has previously shown that treatment of MDA-MB-231 cells with the small-molecule 
cathepsin inhibitor E64 (trans-Epoxysuccinyl-L-leucylamido(4-guanidino)butane) can 
increase the amount of active cathepsin S, while decreasing the amount of active cathepsin 
L in breast cancer cells [50]. The underlying mechanism responsible for this unexpected 
reaction to inhibitor treatment has not been previously established. Developing 
experimental and computational tools to study the dynamic proteolytic regulatory network 
responsible for generating these unintuitive results is critical for the future development of 
safe and effective cathepsin inhibition strategies for the prevention of cancer metastasis 
and other pathologies. 
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2.3 Biological Challenges of Computationally Modeling Cathepsin Dynamics 
2.3.1 Cathepsin “lifecycle” 
 In most cell types cysteine cathepsins are translated as preprocathepsins in the 
rough endoplasmic reticulum (ER) (Figure 2-1). Signal peptides target them to the 
endoplasmic reticulum lumen where the signal peptides are cleaved by signal peptidases, 
yielding procathepsins. Procathepsins are then post-translationally modified by 
glycosylation with high-mannose glycans. Procathepsins then pass through the Golgi and 
enter the trans-Golgi network where mannose residues are phosphorylated yielding 
mannose 6-phosphate (M6P) tags that drive their sorting into vesicles bound for late 
endosomes. Procathepsins are then activated to their mature forms in low pH environments, 
through the removal of their propeptide either autocatalytically, by other cathepsins, or by 
legumain/asparaginyl lysosomal endopeptidases as the late endosomes mature and fuse 
with lysosomes [16, 51-53]. In addition to this canonical pathway, under disease states or 
cathepsin overexpression conditions, cathepsins can overrun the Golgi pathway, bypassing 
M6P sorting and leading to secretion of inactive procathepsins [54, 55]. Macrophages are 
also known to secrete lysosomal enzymes under normal culture conditions and in response 
to stimuli such as hypoxia [56, 57].  
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Figure 2-1: Overview of the cysteine cathepsin lifecycle in mammalian cells. Cathepsins 
are translated in the endoplasmic reticulum as inactive zymogens known as 
preprocathepsins where they are targeted to the ER lumen by leader sequences. The 
prepropeptide is cleaved and the inactive proenzymes are transported to the Golgi 
apparatus after proper protein folding. In the Golgi, procathepsins are targeted for secretion 
or transport through endolysosomal vesicles by glycosylation and mannose-6-
phosphorylation. Procathepsins are activated to their mature forms by cleavage of the 
propeptide accomplished through a combination of autocatalytic or protease-mediated 
hydrolysis accelerated by the increasingly acidic and reducing environment of maturing 
endosomes. In some cells, mature cathepsins can be transported from endosomes and 
lysosomes to the plasma membrane for secretion, or entire endosomes and lysosomes can 
fuse with the plasma membrane releasing their contents to the extracellular space. In some 
cells, extracellular procathepsins and mature cathepsins can be endocytosed leading to 
intracellular cathepsin accumulation. 
 
2.3.2 Cathepsin trafficking 
 Protein trafficking is an important consideration for cathepsin mathematical and 
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conditions of their microenvironment. Procathepsins activate to their mature forms by 
cleavage of the propeptide under acidic conditions. This reaction can proceed 
autocatalytically or when catalyzed by another protease. Catalysis by ancillary proteases is 
also dependent on the environment, as the pH, redox, and presence of proteases, inhibitors 
and substrates all affect the activation process. 
 Secretion of inactive procathepsins or active mature cathepsins into the 
extracellular environment can drastically alter the proteolytic dynamics surrounding the 
cell, as substrates are degraded, endogenous inhibitors bind to the proteases and proteases 
become inactivated or degraded. Cathepsin inactivation, distinct from inhibition which 
requires an inhibitor, is not currently well understood, but is thought to encompass 
denaturation of the protein as well as oxidation of the active site cysteine and possibly some 
other currently unknown mechanisms including degradation by other proteases, a 
hypothesis postulated by our research team. Mature cathepsins can inactivate, particularly 
in the absence of substrates or inhibitors, resulting in enzyme that has not been degraded, 
but is unable to degrade other proteins. 
2.3.3 Limitations of cathepsin animal models 
 Animal models have been instrumental to cathepsin research, establishing links 
between cathepsins and atherosclerosis, vascular repair, antigen presentation, cancer 
metastasis and more [58-61]. However, some fundamental biological differences between 
human and non-human proteases make cathepsin animal models challenging. While mouse 
cells express cathepsins B, L, S and K, they do not express cathepsin V. Confusingly mouse 
cathepsin L is the homolog to human cathepsin V, since it shares greater sequence identity 
with human cathepsin V than with human cathepsin L [62]. The case of odanacatib, a 
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cathepsin K inhibitor that underwent clinical trials for the treatment of osteoporosis and 
cancer metastasis, highlights another limitation of animal models. While odanacatib is an 
effective inhibitor of human cathepsin K, with a Ki of 0.18 ± 0.06 nM, it is much less 
effective at inhibiting mouse cathepsin K, with a Ki of 32.7 ± 6.8 nM, resulting in a 182 
fold lower effectiveness of inhibition of mouse cathepsin K compared to human cathepsin 
K despite 86% sequence similarity between the two enzymes [63]. Odanacatib is likely not 
unique as a species-specific cathepsin inhibitor. The development and validation of better 
human cathepsin mathematical and computational models would not only reduce time and 
cost compared to using animal models, but increase the likelihood of identifying effective 
inhibitors for the treatment of human disease. 
2.4 Approaches to computationally model cathepsin activity 
 In vitro and in vivo experiments on cathepsin dynamics are the gold standard, but 
these studies can be extremely costly and time consuming. Computational and 
mathematical modeling based on, and validated using, experimental data provides an 
alternative approach to hypothesis generation and testing necessary to unravel this 
complicated network of interactions incorporating the lifetimes and potency of this family 
of enzymes. 
2.4.1 Substrate degradation and enzyme kinetics 
 The earliest uses of mathematical and computational modeling in cathepsin 
research relied on Michaelis-Menten (MM) principles of enzyme kinetics. Since then, more 
advanced modeling techniques have been employed on many different cathepsin family 
members. While substrate degradation by cathepsins can be represented with MM models, 
cathepsin activation and inactivation necessitate additional mathematical terms. Enzyme 
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kinetics and inhibition of different cathepsins have been described on different natural and 
artificial substrates, including elastin [64]. 
 Mathematical modeling has been fundamental to discovering the complex role of 
ancillary molecules and inhibitors in cathepsin activity. Kinetic modeling of cathepsin K 
was used to describe the mechanisms by which glycosaminoglycans (GAGs) promote 
cathepsin K degradation of collagen [65]. Kinetic modeling has been used to investigate 
the poorly understood mechanisms related to cathepsin K inactivation and it has identified 
clusterin as a ‘liberator’ of cathepsin K, a molecule that protects an enzyme from inhibition 
without affecting the enzyme’s activity [66]. Kinetic modeling of inhibition of cathepsin B 
by cystatin C identified a two-step inhibition process, involving the occluding loop of 
cystatin B, responsible for cathepsin B’s observed resistance to cystatin C inhibition 
compared to other closely related cysteine cathepsins [67]. 
2.4.2 Ordinary differential equation modeling 
 Building on the foundation of work laid by kinetic modeling, mechanistic ordinary 
differential equation (ODE) modeling based on the law of mass action has been used to 
discover new mechanisms of cathepsin regulation. Several properties of these models make 
them attractive to cathepsin research, including their ability to incorporate dynamics, model 
continuous solutions and include multiple compartments. ODE models are able to simulate 
enzyme dynamics with different model species changing over time. This is useful when 
studying cathepsins because time sensitive reactions, including activation, removal of the 
propeptide, and inactivation, denaturation or oxidation of active site residues, can modify 
the ability of cathepsins to degrade substrates in a time dependent manner. ODE models 
can be used to generate continuous solutions, which allow for interpolation between 
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discrete data points. Utilizing multiple ODEs allows for the modeling of multi-
compartment systems, allowing ODE models to incorporate movement of model species, 
such as secretion from intracellular to extracellular compartments. 
 ODE modeling is a well characterized and flexible tool that has been used 
extensively in systems biology to analyze metabolism, genetic regulation, cellular 
signaling and many other biological processes [68]. Applying this technique to cathepsins 
allows us to build on standardized methods and tools to formulate model diagrams, convert 
them into equations, estimate parameters and analyze the system under different 
conditions. Depending on the exact formulation of the model equations, the parameters 
attached to mechanistic ODE models can closely correspond to biologically observed 
reaction rates, allowing for relatively straightforward insights into the biological system 
being modeled (e.g. secretion rate in the model directly predicts how quickly cells are 
secreting an enzyme). This is in contrast to more abstract model formulations, where the 
model is able to fit the experimental data, but the parameters do not correspond directly 
components of the biological system.  
 The main limitations of ODE modeling are the assumptions inherent to the law of 
mass action and difficulties encountered in parameter estimation. The law of mass action 
assumes species in a compartment are completely mixed and able to freely move and 
interact with other species in the compartment. These assumptions are rarely completely 
satisfied in cellular systems, but well parameterized ODE models offer reasonable 
approximations of these systems while requiring significantly less computational resources 
than more intensive methods such as reaction-diffusion modeling. Determining the best 
parameters for an ODE model system based on experimental data is currently an unsolved 
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problem that is often addressed on a model-to-model basis. Computational optimization 
algorithms capable of dealing with large amounts of data have taken great strides in recent 
years, but identifying reasonable parameters is still a time consuming, iterative process. 
Generating and evaluating these potential solutions is a critical part of creating an ODE 
model capable of answering biological questions. Keeping these limitations in mind when 
constructing the initial model can have a major impact on the ability to identify reasonable 
parameters, since parameter estimation complexity increases exponentially as more 
equations and parameters are incorporated into the model. 
 ODE modeling has been used to characterize several systems involving cathepsins, 
substrates and inhibitors. Dynamic interactions between cathepsin B, cystatin C and b-
amyloid aggregation were explored using a mechanistic ODE model, where cathepsin B 
was found to degrade b-amyloid plaques, cystatin C inhibited cathepsin B, but cystatin C 
also bound to b-amyloid precursors [69]. Mechanistic ODE modeling has elucidated 
cathepsin-on-cathepsin interactions between cathepsin S and cathepsin K, termed 
“cathepsin cannibalism” [70]. Further work has shown that these cannibalistic interactions 
are not limited to cathepsins S and K, but encompass cathepsins K, L, S and V with more 
interactions likely to exist (Ferrall-Fairbanks et al. in preparation). The existence of these 
cannibalistic interactions is hypothesized to control substrate degradation both through 
degradation of mature cathepsins, but also through cathepsins acting as “distractions” or 
substrates for other active cathepsins (Ferrall-Fairbanks et al. in preparation). Mechanistic 
ODE modeling also has been used to investigate an observed increase in active cathepsin 
S in cancer cells following treatment with a broad spectrum cathepsin inhibitor [50]. Model 
results indicated that the irreversible, covalently binding cathepsin inhibitor E64 could 
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become unbound from cathepsins under non-reducing SDS-page conditions, suggesting 
the inhibitor might not irreversibly bind the active site cysteine of cathepsins (Shockey et 
al. under review). 
2.4.3 Protein structure modeling 
 Since cathepsins are attractive drug targets for cancer and other diseases such as 
osteoporosis and atherosclerosis, many groups are using computational methods to screen 
and identify potential cathepsin inhibitors. High throughput molecular docking 
successfully identified an allosteric small-molecule inhibitor of cathepsin K, several 
potentially irreversible binding inhibitors of cathepsin B and inhibitors of cathepsin L [71-
73]. A cathepsin S structural model was generated using the X-ray crystal structure of 
cathepsin K, then DOCK software was used to identify a highly potent, nonpeptidic 
noncovalent cathepsin S inhibitor that is highly selective for human cathepsin S compared 
to mouse, dog, monkey and bovine cathepsin S or other closely related human enzymes 
including cathepsins L, F and K [74]. Three-dimensional quantitative structure-activity 
relationship modeling has been used in combination with ligand based pharmacophore 
modeling to identify novel cathepsin L inhibitors from a library of natural compounds [75]. 
A combination of quantum mechanical and molecular mechanical modeling has been used 
to investigate the molecular steps required for cathepsin K cleavage of a peptide substrate, 
identifying the acylation step as rate limiting for proteolysis [76]. 
 Protein structure modeling has also been used to identify substrates and interactions 
with ancillary molecules other than inhibitors. A study on fibrinogen used a combination 
of molecular docking and protein sequence modeling to predict cleavage sites by 
cathepsins K, L and S on fibrin and fibrinogen molecules where cathepsins K, L and S 
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were experimentally confirmed to degrade fibrin [77]. Molecular docking has been used to 
identify allosteric binding sites for heparin on cathepsin B and elucidating the mechanism 
responsible for heparin protecting cathepsin B from inactivation at alkaline pH [78]. 
 Electrostatic modeling of cathepsins at different pHs has also been employed to 
study cathepsin cannibalism. At acidic pH the electrostatics of cathepsins S and K are less 
favorable for binding between the two enzymes, but as the pH becomes neutral the 
electrostatic model predicts more favorable interactions between cathepsins S and K 
(Kieslich et al. in preparation). This increase in electrostatic favorability indicates cathepsin 
cannibalism could be more likely at neutral pH than acidic pH, suggesting cathepsin 
cannibalism could be a natural mechanism for degrading cathepsins that have escaped their 
acidic pH niches. 
2.4.4 Statistical modeling 
 Statistical modeling has seen relatively little use compared to kinetic and structural 
analyses, but the predictive power and flexibility of these models make them useful in non-
mechanistic applications. Statistical modeling using cathepsin expression and kinase 
activation has been used to predict severity of cancer progression and invasiveness, 
identifying patient-specific monocyte phenotypes predictive of tumor invasiveness, 
independent of the cancer cells themselves [79]. Statistical modeling is also useful for 
analysis of cathepsin inhibitor drug trials and designing dosing regimens. Analysis of one 
cathepsin K clinical trial could predict the bone mineral density following different dosages 
of a cathepsin K inhibitor [80]. 
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2.5 Conclusions 
 Cysteine cathepsins are challenging enzymes to study with traditional molecular 
biology techniques. Cathepsin activity is largely regulated post-translationally by a 
dynamic network of proteases, substrates, inhibitors and ancillary molecules. Mathematical 
and computational modeling offer new methods for generating and testing hypotheses in 
protease biology. These techniques have already proved indispensable in understanding 
mechanisms including cathepsin cannibalism and allosteric cathepsin regulation as well as 






3 CHARACTERIZING THE PROTEOLYTIC PROFILES OF 
HUMAN MACROPHAGES  
3.1 Introduction 
 Monocytes and macrophages are key components of the adaptive immune system 
and provide a first line of defense against infection and other pathologies. Circulating 
monocytes extravasate from the blood to sites of injury and inflammation where they 
differentiate into macrophages in response to environmental stimuli including a variety of 
inflammatory cytokines [81]. While macrophages are extremely effective at phagocytosing 
foreign pathogens and stimulating adaptive immune responses through antigen 
presentation, macrophages can actually exacerbate serious pathologies including 
atherosclerosis and multiple types of cancer. Proteases, particularly cysteine cathepsins, 
secreted by macrophages can weaken extracellular matrix barriers, facilitating the 
expansion of smooth muscle cells into the vascular intima or the extravasation of cancer 
cells into the bloodstream leading to cancer metastasis [9, 82]. Characterization of 
monocyte and macrophage proteolytic profiles could provide insights into the mechanisms 
of these pathologies and inform the development of future treatments, particularly 
cathepsin inhibitors. 
 In general, computational modeling of biological systems benefits from absolute 
quantification of biological variables, particularly protein levels. However, many 
biological questions can be answered with experiments that do not quantify variables in an 
absolute sense. This chapter details attempts to quantify the cathepsin profiles of human 
macrophages by measuring active cathepsins with cathepsin zymography and levels of pro 
and mature cathepsin by Western blot. These data are necessary to parameterize models of 
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the proteolytic interactions between tumor associated macrophages and cancer epithelial 
cells, since both these cell types are known to produce and secrete multiple proteases into 
the shared milieu of the tumor microenvironment. Isolating the proteolytic contributions of 
macrophages will allow us to generate personalized tumor models, due to the documented 
variance in cathepsin profiles of macrophages from different people [79, 83]. We also 
document an unexpected response to cathepsin inhibitor treatment, where macrophages 
treated with a cathepsin inhibitor have increased active and pro cathepsins with no 
measurable difference in mature protease. 
3.2 Materials and Methods 
3.2.1 Thp-1 monocyte and macrophage culture and sample collection 
 Undifferentiated Thp-1 monocytes were cultured in suspension in RPMI 1640 
medium (Lonza) supplemented with 10% FBS, 1% L-glutamine and 1% 
Penicillin/Streptomycin. Thp-1 monocytes were serially diluted and different numbers of 
cells were lysed in 50 µL of zymography lysis buffer. For each cell count, 10 µL of lysate 
were analyzed for active proteases by cathepsin zymography. Thp-1 monocytes were 
differentiated into Thp-1 macrophages through treatment with 100 nM phorbol 12-
myristate 13-acetate (PMA) for 24 hours. Following differentiation, macrophages were 
cultured in media containing 10µg/mL cycloheximide for 24 hours to stop protein 
translation. Cells were switched to serum free media after 24 CHX treatment to begin time 
course measuring secreted cathepsins. At each time point, cell media was collected and 
acetone precipitated by mixing 5:1 acetone to media, holding on ice for 30 minutes, then 
spinning at 3000g for 10 min, before aspirating acetone and resuspending protein 
precipitate in 100 µL zymography lysis buffer for a final concentration of 10x. 
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Macrophages were lysed in plate with zymography lysis buffer. Macrophages treated with 
E64 were differentiated with PMA as described above then incubated with different 
concentrations of E64 for 24 hours. 
3.2.2 Multiplex cathepsin zymography 
 Equal volumes of Thp-1 monocyte lysate, equal volumes of Thp-1 macrophage 
media and equal protein amounts of Thp-1 macrophage lysate, were mixed with 
nonreducing SDS-PAGE loading buffer and cathepsin zymography was performed as 
previously described [84, 85]. Briefly, samples were loaded into a gelatin-embedded 
polyacrylamide, lysate proteins were separated by molecular weight during 
electrophoresis. Following electrophoresis, cathepsins were renatured in polyacrylamide 
gels before being incubated overnight in cathepsin-specific assay buffer at 37°C. The gels 
were then stained with Coomassie Blue, then destained. White bands indicate the presence 
of active cathepsins capable of degrading gelatin embedded in the polyacrylamide gel. 
Total protein concentration of cell lysate was measured using the Pierce Micro BCA 
Protein Assay (Thermo Scientific). 
3.2.3 Western blot 
 Total protein concentration in cell lysate was determined by BCA, then equal 
amounts of protein were mixed with reducing loading dye, briefly boiled, then loaded into 
12.5% polyacrylamide gels and separated by electrophoresis. Proteins were transferred 
onto nitrocellulose membranes, blocked and probed with primary antibodies for human 
cathepsin S (R&D Systems) and human cathepsin L (R&D Systems). Membranes were 
probed with secondary antibodies (LI-COR) then imaged on a LI-COR Odyssey CLx 
Imaging System.  
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3.2.4 Statistical analysis 
 Western blot and zymography band intensities were quantified by densitometry in 
ImageJ and data were normalized by dividing each band intensity on a gel by the intensity 
measured from cells treated with PMA and 0 µM E64 (setting this group to 1 across all 




3.3.1 Active cathepsin V detectable in 1.5 µg of protein in Thp-1 monocyte lysate 
 Cathepsin zymography is a useful method for measuring active cathepsins in a 
variety of cell and tissue samples. Assessing zymography results from homogenized tissues 
like breast tumors requires validation for the expected signal and limits of detection of 
different types of cells that could be contributing proteases to the tissue. Active cathepsins 
were detectable across all cell counts down to 100,000 cells, with 50,000 cells not 
producing a detectable zymography signal (Figure 3-1A). Total protein content of the 
lysate samples was quantified by bicinchoninic acid (BCA) assay and plotted against cell 
count (Figure 3-1B). Assuming complete lysing of Thp-1 monocytes, 20% of cell lysate 
was analyzed by cathepsin zymography indicating active cathepsins can be detected in the 
lysate of as few as 20,000 cells. The measured total protein concentration of the 100,000 
cell lysate was 0.1534 µg/µL, of which 10 µL were loaded for zymography, indicating 
active cathepsins can be detected in as little as 1.5 µg of protein from Thp-1 monocyte 
lysate. 
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 Comparison to a recombinant cathepsin V standard curve was used to determine 
the amount of intracellular active cathepsin V in Thp-1 monocytes. Serially diluted 
recombinant cathepsin V and Thp-1 monocytes were loaded and analyzed by cathepsin 
zymography (Figure 3-2A). Results were quantified by densitometry and the standard 
curve of known amounts of active cathepsin V were used to calculate the active cathepsin 
V content of the different numbers of Thp-1 monocytes (Figure 3-2B). The calculated 
active cathepsin V content of a single Thp-1 macrophage is 53.6 pg. The reported volume 
of human monocytes is between 46.8 to 78.38 µm3 [86]. The estimated volume of 
lysosomes, where cathepsin V is assumed to reside, is 2.5% of cell volume in human 
macrophages, corresponding or 1.17 to 1.96 µm3 [87]. Assuming monocytes have a similar 
relative lysosomal volume compared to macrophages yields an estimated active cathepsin 
V concentration of between 1.1 to 1.8M in lysosomes of Thp-1 monocytes.  
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Figure 3-1: Active cathepsins from 100,000 Thp-1 monocytes detectable by cathepsin 
zymography. Thp-1 monocytes were serially diluted and lysed in 50 µL cathepsin 
zymography buffer. Active cathepsins were detectable at all cell counts greater than 50,000 
cells (A). Total protein concentration of Thp-1 lysate was quantified by BCA. Protein 



































Figure 3-2: Active cathepsin V content of Thp-1 monocytes. Thp-1 monocytes were 
serially diluted and lysed in 50 µL cathepsin zymography buffer, and equal volumes of 
Thp-1 lysate and a recombinant cathepsin V standard curve were analyzed by cathepsin 
zymography (A). Active cathepsins were quantified by densitometry and active cathepsin 
V content of Thp-1 monocytes was calculated by comparison with the recombinant 
cathepsin V standard curve. 
 
3.3.2 Quantifying dynamics of cathepsins L and S in Thp-1 macrophages 
 Macrophages, particularly macrophages in tumors and other sites of inflammation, 
are known to produce and secrete a variety of proteases, but the precise rates of production 
and secretion of these proteases have not been well characterized [88, 89]. Intracellular 
protein levels result from a constant balance of transcription, translation, secretion and 
degradation. Measuring steady state levels of intracellular proteins is relatively 
straightforward but determining the rates of influx and efflux of specific proteins can be 
more challenging due to the variety of cellular processes constantly influencing protein 
concentration. Interrupting one of these processes can provide the perturbation of the 
0.01 0.05 0.5 1
Recombinant Cathepsin V (ng) Thp1 (1x104)






























system necessary to better understand the balance of processes leading to cellular 
homeostasis.  
  To better characterize the rates of intra- and extracellular accumulation of 
cathepsins L and S in macrophages, we interrupted protein production with the translation 
inhibitor cycloheximide. Thp-1 monocytes were differentiated into macrophages by 
stimulation with phorbol 12-myristate 13-acetate (PMA), then incubated with 
cycloheximide (CHX) for 24 hours to halt protein synthesis. A time course of lysate and 
media was collected over the next 24 hours and expression of cathepsins L and S was 
measured by Western blot (Figure 3-3 & Figure 3-4). This experiment revealed cathepsins 
L and S have markedly different intracellular dynamics in Thp-1 macrophages. 
Intracellular pro- and mature cathepsin L was almost completely undetectable after 24 
hours of CHX treatment, indicating that cathepsin L is quickly degraded or secreted. After 
removal of CHX, steady state levels of cathepsin L rebounded, pointing to high 
intracellular turnover of cathepsin L (Figure 3-3A). In contrast, levels of cathepsin S 
remained relatively constant after CHX treatment to the end of the 24-hour time course, 
suggesting cathepsin S has greater intracellular stability than cathepsin L, and is potentially 
produced, secreted and degraded more slowly than cathepsin L (Figure 3-3B). 
 A similar dynamic was observed extracellularly, where procathepsin L was 
secreted more quickly than procathepsin S but plateaued by 4 hours indicating that it is 
likely degraded extracellularly (Figure 3-4A). Mature cathepsin L appeared to reach steady 
state by 8 hours, accumulating more slowly than procathepsin L, likely due to both a slow 
secretion of mature cathepsin L and extracellular activation of procathepsin L to mature. 
Extracellular pro and mature cathepsin S accumulated at similar relative rates, increasing 
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linearly throughout the entire 24-hour time course suggesting a relatively slow rate of 
secretion coupled with a low rate of extracellular cathepsin S activation and degradation. 
 
Figure 3-3: Translation inhibitor depletes cathepsin L but not cathepsin S in Thp-1 
macrophages. Thp-1 monocytes were differentiated into macrophages by PMA treatment, 
then incubated with the translation inhibitor cycloheximide (CHX) for 24 hours. Cells were 
changed to fresh media and a time course of lysate was collected over 24 hours. Pro- and 
mature cathepsin L (A) and cathepsin S (B) content were measured by Western blot and 
quantified by densitometry. Intracellular pro- and mature cathepsin L was almost 
undetectable following 24 hours of CHX treatment. Procathepsin L increased linearly for 
the first 8 hours, plateauing before 24 hours. Mature cathepsin L increased linearly for the 
entire 24 hour time course. Procathepsin S was present after CHX treatment, only 
accumulating slightly over 24 hours. Mature cathepsin S was also detectable after CHX 
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Figure 3-4: Cathepsin L accumulates more quickly than cathepsin S in Thp-1 media. Thp-
1 monocytes were differentiated into macrophages by PMA treatment, then incubated with 
the translation inhibitor cycloheximide (CHX) for 24 hours. Cells were changed to fresh 
media and a time course of media was collected over 24 hours. Pro- and mature cathepsin 
L (A) and cathepsin S (B) content were measured by Western blot and quantified by 
densitometry. Pro and mature cathepsin L accumulated rapidly over the first 4 hours before 
plateauing by 8 hours, with procathepsin L declining slightly by 24 hours. Pro and mature 
cathepsin S accumulated linearly, but more slowly than cathepsin L (n=2). 
 
3.3.3 Cathepsin inhibition stimulates increased active cathepsins in macrophages 
 Pharmaceutical small molecule cathepsin inhibitors are currently under 
investigation to treat a variety of pathologies including osteoporosis and cancer metastasis 
[44]. We decided to explore the impacts of cathepsin inhibition on the proteolytic profiles 
of macrophages by treating Thp-1 macrophages with the broad-spectrum cathepsin 
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inhibitor E64 and measuring active cathepsins by cathepsin zymography (Figure 3-5). We 
hypothesized that E64 would decrease active cathepsin levels in Thp-1 macrophages, 
because it is a broad spectrum irreversibly binding cathepsin inhibitor. Unexpectedly, 
treatment with the cathepsin inhibitor caused an increase in the amounts of active 
cathepsins V and S, while decreasing the amount of active cathepsin L in a dose dependent 
manner.  Amounts of active V, S and L were increased in Thp-1 macrophages differentiated 
by PMA treatment, compared to Thp-1 monocytes, consistent with their differentiation 
towards a macrophage phenotype. 
 
Figure 3-5: Macrophages have reduced amounts of active cathepsin L after incubation with 
E64, but higher amounts of active cathepsins S and V. Thp-1 monocytes were stimulated 
to differentiate into macrophages with PMA, and confirmed by the upregulated amounts 
of active cathepsins L, S, and V. These differentiated macrophages were then incubated 
with 0, 5, or 50 μM E64 for 24 hours, lysed, and equal amounts of protein were loaded for 
multiplex cathepsin zymography. E-64 incubation caused an 80% loss of active cathepsin 
L in the macrophages at 50 µM dose, but two-fold amounts of active cathepsin S and 
cathepsin V (n=7-9, * p < 0.05, # p < 0.001 by two-tailed t-test), as quantified and shown 
in the densitometry. 
 
 To determine if the measured increases in active cathepsins were due to increased 
protein expression, we measured cathepsin L and S levels in E64 treated Thp-1 
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L were  significantly increased after treatment with 50 µM E64 (Figure 3-6B). An increase 
in mature cathepsin S was consistent with the observed increase in active cathepsin S 
detectable by zymography. Pro- and mature cathepsins L and S were significantly increased 
after PMA stimulated differentiation.  
 
Figure 3-6: Cathepsin inhibitor treatment increases cathepsin L and S in Thp-1 
macrophages.  
Thp-1 monocytes were differentiated into macrophages by PMA treatment and incubated 
with the cathepsin inhibitor E64 for 24 hours. Cathepsin L and S levels were measured by 
Western blot. PMA treatment increased pro and mature cathepsins L and S in Thp-1 
macrophages. Pro and mature cathepsin S and pro cathepsin L were increased in cells 
treated with 50 µM E64 (n=3 * p < 0.05, % p < 0.01 by two-tailed t-test). 
 
3.4 Discussion 
 Different protein assays were used to quantify the cathepsin levels in human Thp-
1 monocytes and macrophages. Active cathepsins, particularly cathepsin V, were 
detectable in as little as 1.5 µg of protein from Thp-1 lysate. The active cathepsin V content 
of a Thp-1 monocyte was calculated to be 53.6 pg, with a potential lysosomal concentration 
of between 1.1 to 1.8M. Intra- and extracellular dynamics of cathepsins S and L were 
shown to be quite distinct from each other in Thp-1 macrophages, with cathepsin L 
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production, secretion and turnover being significantly higher than cathepsin S. Finally, 
treatment with the cathepsin inhibitor E64 increased active cathepsins V and S in 
macrophages while decreasing active cathepsin L. E64 treatment caused a corresponding 
increase in pro and mature cathepsin S, consistent with their increased active levels 
measured by zymography. Interestingly, mature cathepsin L did not change in response to 
E64, despite a drop in zymography detectable active protein. Procathepsin L levels 
increased after E64 treatment, pointing to a reduced potential for intracellular activation of 
cathepsin L following E64 treatment consistent with cathepsin L or other cysteine proteases 
activating L in lysosomes.  
 CHX treatment for 24 hours almost completely depleted pro- and mature cathepsin 
L levels in Thp-1 macrophages. Interestingly, both intra- and extracellular levels of 
procathepsin L accumulated quickly and reached steady state levels 8 hours after CHX was 
removed. Intracellular cathepsin L reaching a steady state is not particularly surprising, 
since lysosome biogenesis, including the production of lysosomal proteases, is under 
transcriptional control and denatured cathepsin L can be degraded in lysosomes [90, 91]. 
Extracellular cathepsin L levels reaching steady state is more surprising, since they suggest 
some extracellular degradation of cathepsin L or a modulation in the production or 
secretion of cathepsin L by macrophages in response to concentration of cathepsin L or 
some other control mechanism. A likely scenario is an initial ramp-up in cathepsin L 
production and secretion post-CHX treatment, then some unknown regulatory process 
turns down synthesis of new enzyme, possibly cathepsin B controlling lysosomal 
biogenesis [92]. Notably, extracellular procathepsin L levels actually reach steady state by 
4 hours, while intracellular procathepsin L continues to increase for an additional 4 hours 
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after the end of CHX treatment. Extracellular cathepsin L levels stabilizing before 
intracellular levels further supports the hypothesis of extracellular cathepsin L degradation 
since it is unlikely cathepsin L secretion was stopped entirely at an earlier time point, while 
intracellular cathepsins continued to accumulate and reached steady state hours later. 
 Active cathepsins V and S increasing in response to E64 treatment, while active 
cathepsin L decreases, is a surprising result since E64 is a broad spectrum cysteine 
cathepsin inhibitor that is thought to bind irreversibly to  the cysteine in the active site of 
these enzymes [93]. An increase in procathepsin L following inhibitor treatment could 
point to cathepsin inhibition causing a decrease in reported autocatalytic activation of 
procathepsin L [94]. The increase in both pro- and mature cathepsin S suggests an increase 
in protein production, or decrease in protein secretion, rather than just a change in 
activation from pro to mature enzyme. Additional experiments will be required to 
determine any possible transcriptional regulation, or changes in enzyme secretion, 
impacted by E64 treatment. Additional experimental evidence will be required to 
investigate the effects E64 has on total cathepsin V protein levels as well. A similar 
response to E64 treatment by cathepsins L and S in breast cancer cells has been documented 
previously [50] and this analysis is extended to other breast cancer cell lines and primary 






4 CATHEPSIN DYNAMICS IN MULTICELLULAR SYSTEMS 
4.1 Introduction 
 For many years, it was accepted that cathepsin activity was confined to specific 
intracellular compartments, particularly endolysosomal vesicles, where the acidic pH and 
reducing environment are amenable to cathepsins playing roles in antigen presentation and 
bulk protein turnover [91, 95]. More recent work has documented cathepsins in non-
lysosomal intra and extracellular environments under healthy and pathologic conditions. 
Cathepsins have been identified in the cytoplasm, nucleus and mitochondria, as well as 
extracellularly where they are involved in extracellular matrix remodeling and cleavage of 
cell adhesion molecules [50, 96-98]. 
 Following its discovery, cathepsin K was thought to be almost exclusively found in 
osteoclasts, where it plays a pivotal role in degrading type I collagen during bone resorption 
[99]. Since then, cathepsin K has been implicated in numerous cancers including breast 
and prostate [42, 100]. Cathepsin K is present both at primary tumor sites, as well as 
secondary metastatic sites particularly in the bone, and cathepsin K inhibition can decrease 
bone metastases among breast cancer patients [32]. Macrophages and other antigen 
presenting cells are known to produce and secrete cathepsin S, particularly under 
inflammatory conditions [101, 102]. Macrophages in bone metastatic sites of prostate 
cancer have also been shown to produce cathepsin K [60]. 
 While cathepsins are potent degraders of extracellular matrix proteins, including 
collagen, elastin and laminin, cathepsin S has been shown to degrade cathepsin K in vitro 
even in the presence of matrix substrates [70]. Since cathepsin cannibalism was first 
discovered, a combination of recombinant enzyme experiments and computational 
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modeling techniques have identified likely cannibalistic interactions including: cathepsin 
S on cathepsin K, cathepsin K on cathepsin L, cathepsin L on cathepsin K and cathepsin K 
autodegradation [103]. Autodegradation has been observed previously in some proteases 
with wide substrate specificities, including human trypsin and bacterial thermolysin, but 
seems to be rarer among less promiscuous proteases [104, 105].  
 While cathepsin cannibalism has been measured in vitro, it has not been observed 
in cells. We sought to create a cellular system, where the effects of cathepsin cannibalism 
between cathepsins S and K could be observed. Data from these cellular experiments was 
used to parameterize a mathematical model capable of predicting the relative contributions 
of cathepsins S and K to cathepsin K degradation. 
 
4.2 Materials and Methods 
4.2.1 Fluorescently quenched elastin to measure cathepsin proteolysis 
 Five picomolar recombinant cathepsins S and K were incubated alone and in 
combination in serum-free DMEM containing 0.05mg/ml DQ elastin at 37°C. 
Fluorescence was measured at 10-minute intervals for 2 hours. Background fluorescence 
(measured with media containing DQ elastin control) was subtracted out of all reported 
measurements. 
4.2.2 Generation of cathepsin overexpressing cell lines 
 HEK293T cells were stably transfected with plasmids coding for 6x-Histidne 
tagged wildtype and mutant cathepsins as previously described [103]. Cells were 
transfected with linearized cathepsin plasmids using lipofectamine 2000 (Invitrogen) and 
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then cultured in selection antibiotics for 4 weeks to ensure integration of plasmid DNA into 
the cell genome.  
4.2.3 Coculture of cathepsin overexpressing HEK293T cells 
 HEK293T cells were cultured in DMEM (Lonza, supplemented with 10% FBS, 1% 
L-glutamine, 1% Penicillin/Streptomycin) and seeded in 6 well plates at 100,000 total cells 
per well overnight (e.g. 50,000 cathepsin K producing cells and 50,000 cathepsin S cells). 
Cells were washed with PBS then switched to DMEM without FBS. After 24 hours, media 
was collected and centrifugally concentrated ~10 fold in Vivaspin 500 concentrators 
(15,000g, 40 minutes, 4°C) before storing concentrated media at -80°C. Cells were lysed 
in zymography lysis buffer, sonicated and stored at -80°C.  
4.2.4 Western blot 
 Total protein concentration in cell lysate and concentrated media was determined 
by BCA, then equal amounts of protein were mixed with reducing loading dye, briefly 
boiled, then loaded into 12.5% polyacrylamide gels and separated by electrophoresis. 
Proteins were transferred onto nitrocellulose membranes, blocked and probed with primary 
antibodies for human cathepsin K (Proteintech) and human cathepsin S (R&D Systems). 
Membranes were probed with secondary antibodies (LI-COR) then imaged on a LI-COR 
Odyssey CLx Imaging System.  
4.2.5 Time course of cathepsin accumulation in media of cathepsin overexpressing 
cells for dynamic model fitting 
 HEK293T cells (cathepsin S producing cells alone, cathepsin K producing cells 
alone or cathepsin S and cathepsin K coculture) were seeded in 6 well plates at 100,000 
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total cells per well overnight. Cells were washed with PBS then switched to DMEM 
without FBS. Media was collected after 0, 2, 4, 6, 8 and 24 hours and concentrated by 
adding 5 mL of cold acetone per 1 mL of cell culture media, incubating on ice for 30 
minutes, then collecting the protein precipitate by centrifugation (3000g, 10 minutes, 4°C) 
and resuspending in a volume of lysis buffer resulting in a 10 fold concentration. Amounts 
of pro- and mature cathepsins S and K were measured by Western blots loaded with 
standards of known amounts of recombinant cathepsins. Absolute amounts of cathepsins 
in the cell culture media were estimated by comparing sample bands to the recombinant 
standard curve and calculating molar concentrations in the original, unconcentrated 
conditioned media. 
4.2.6 Systems biology modeling of cathepsin K and S producing cells 
 The following system of ordinary differential equations was developed to model 
the protein dynamics in the media of cathepsin overexpressing HEK293Ts based on the 
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= 𝑘C$BC[𝑀𝑎𝑡𝐾]K − 𝑘C$FFC[𝑀𝑎𝑡𝐾_𝑀𝑎𝑡𝐾] − 𝑘CH;&C[𝑀𝑎𝑡𝐾_𝑀𝑎𝑡𝐾]             (8) 
 
Independent Variables: 
Scells = Number of cathepsin S producing cells (0, 1 or 2) 
Kcells = Number of cathepsin K producing cells (0, 1 or 2) 
 
Dependent Variables: 
ProS = Free procathepsin S 
MatS = Free mature cathepsin S 
ProK = Free procathepsin K 
MatK = Free mature cathepsin K 
MatS_ProK	= Mature cathepsin S bound to procathepsin K 
MatS_MatK = Mature cathepsin S bound to mature cathepsin K 
MatK_ProK = Mature cathepsin K bound to procathepsin K 
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MatK_MatK = Mature cathepsin K bound to mature cathepsin K 
 
Parameters: 
kSsec = rate of secretion of procathepsin S 
kSact = rate of activation of procathepsin S to mature cathepsin S 
kSdeg = rate of bulk loss of mature cathepsin S from the system 
kKsec = rate of secretion of procathepsin K 
kKact = rate of activation of procathepsin K to mature cathepsin K 
kKdeg = rate of bulk loss of mature cathepsin K from the system 
kSonK = rate of binding of mature cathepsin S to pro or mature cathepsin K 
kSoffK = rate of unbinding of mature cathepsin S from pro or mature cathepsin K 
kScatK = rate of catalysis of pro or mature cathepsin K by mature cathepsin S 
kKonK = rate of binding of mature cathepsin K to pro or mature cathepsin K 
kKoffK = rate of unbinding of mature cathepsin K from pro or mature cathepsin K 
kKcatK = rate of catalysis of pro or mature cathepsin K by mature cathepsin K 
 
 Model equations were implemented in COPASI [106]. Parameter estimation was 
carried out using COPASI’s built-in genetic algorithm. The full details of parameter 
estimation methodology are described in Appendix 2. 
4.2.7 Coculture of cathepsin overexpressing cells and macrophages with cathepsin 
inhibitor treatment and mRNA transfection 
 Thp-1 human monocytes were cultured in RPMI (Lonza, supplemented with 10% 
FBS, 1% L-glutamine, 1% Penicillin/Streptomycin) and differentiated into macrophages 
on 6 well plates at a density of 50,000 cells per well using 0.1uM phorbol 12-myristate 13-
acetate (PMA) for 24 hours. Macrophages were switched to DMEM (Lonza, supplemented 
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with 10% FBS, 1% L-glutamine, 1% Penicillin/Streptomycin) for 24 hours, then wildtype 
or cathepsin K overexpressing HEK293T cells were added to the wells containing 
macrophages at a density of 50,000 cells and cultured overnight. The cells were washed 
with PBS and DMEM without FBS was added and collected after 24 hours. Cells were 
treated with vehicle, 50 µM E64 or cystatin C mRNA. Media was concentrated by adding 
5 mL of cold acetone per 1 mL of cell culture media, incubating on ice for 30 minutes, then 
collecting the protein precipitate by centrifugation (3000g, 10 minutes, 4°C) and 
resuspending in a volume of lysis buffer resulting in a 10 fold concentration. Cells were 
lysed with zymography lysis buffer and sonicated. Concentrated media and lysate samples 
were stored at -80°C.   
4.2.8 Transfection of cells with cystatin C mRNA 
 HEK293T cell Thp-1 macrophage cocultures were transfected with 8 µl of 
Lipofectamine 2000 was diluted in 100 µl of Opti-MEM reduced serum media and 4 µg of 
mRNA was diluted in 100 µl of Opti-MEM. Lipofectamine 2000 and diluted mRNA were 
mixed in equal amounts then Lipofectamine 2000-mRNA complexes were allowed to form 
for 5 minutes at room temperature. After incubation, 200 µl of complexes were added to 
each well for transfection. The total volume of media (DMEM and Opti-MEM) in 
transfected wells was equivalent to vehicle and E64 treated cells. For additional details on 
mRNA transfection, see Chapter 5. 
4.2.9 Statistical analysis 
 Western blot band intensities were quantified by densitometry in ImageJ and data 
were normalized by dividing each band intensity on a gel by the intensity measured from 
either wildtype and cathepsin K or wildtype and cathepsin S HEK cells (setting these 
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groups to 1 across all membranes). Two-tailed Student’s t-test with two-sample equal 
variance was performed on all statistical analysis. 
 
4.3 Results 
4.3.1 Cathepsins S and K interact in media in the presence of substrate 
 To test whether cathepsin S on K cannibalism can occur under cell culture 
conditions, recombinant cathepsins S and K were incubated in media alone and in 
combination with the fluorescently quenched substrate DQ Elastin and fluorescence was 
measured over time (Figure 4-1). Both cathepsins K and S degraded DQ Elastin, though 
cathepsin S produced much more fluorescence over a longer period than cathepsin K, 
consistent with known higher stability and activity of cathepsin S at neutral pH [29]. When 
cathepsins K and S were coincubated, greater substrate degradation was achieved than by 
either separately. However, the total fluorescence was less than predicted by adding 
together the fluorescence generated by each enzyme individually, indicating the two 
enzymes are interacting in some way. The predicted and actual cathepsin K and S outputs 
are quite similar for the first 30 minutes of incubation, but diverge by 40 minutes with the 




Figure 4-1: Cathepsins S and K interact in media in the presence of substrate.   
Recombinant cathepsins K and S were incubated in cell culture media containing DQ 
Elastin and fluorescence was measured over time. Cathepsin S alone (blue dotted line) 
generated significantly more fluorescence than cathepsin K alone (red dotted line). When 
the two enzymes were incubated together they generated more fluorescence than either 
enzyme alone (black dotted line), however they generated less fluorescence than the 
expected sum of the two enzymes (gray solid line). The predicted fluorescence diverged 
from the measured coincubation after 30 minutes (n=2). 
 
4.3.2 Coculture with cathepsin K and cathepsin S producing cells reduces 
procathepsin K in conditioned media 
 Cathepsin S and K cells, which were transfected to stably produce cathepsins under 
a constitutive promoter, were used as an experimental model of cathepsin cannibalism 
between tumor associated macrophages and breast cancer cells. Macrophages are known 
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pericellular elastinolysis [101]. Cathepsin K has been identified in primary breast tumors 
as well as metastatic sites in the bone [107].  Equal numbers of cathepsin S and K 
overexpressing HEKs were cocultured. Additional experimental groups substituted either 
CatS, CatK or both for wildtype (wt), CatS or CatK overexpressing cells resulting in six 
experimental groups: wt+wt, wt+CatS, wt+CatK, CatS+CatK, CatS+CatS, and 
CatK+CatK. We hypothesized that cathepsin S produced by cathepsin S cells would 
degrade cathepsin K produced by CatK cells, resulting in lower cathepsin K levels in media 
and lysate in the CatS+CatK group compared to the wt+CatK group. 
 Cells were seeded and cultured overnight, then switched to serum-free media for 
24 hours to allow for protein secretion before media was collected to determine 
accumulation of cathepsins K and S in the media. Media was centrifugally concentrated 
and cells were lysed to determine if intracellular amounts of cathepsins K and S were 
affected by coculture. Protein concentration was measured by BCA, and equal amounts of 
lysate and media proteins were analyzed by Western blot (Figure 4-2). Procathepsin K was 
significantly lower in media when equal numbers of cathepsin K and S overexpressing 
cells were cocultured compared to equal numbers of cathepsin K overexpressing and 
wildtype cells, suggesting cathepsin S was able to degrade procathepsin K under normal 
cell culture conditions. This confirms the original hypothesis that cathepsin S is capable of 
cannibalizing cathepsin K in a cellular system. Mature cathepsin K, as well as pro- and 
mature cathepsin S, in the media was not significantly different between CatS+CatK and 
wt+CatK cells, suggesting cannibalism does not have a large impact on these species in 
this system, possibly due to the relatively low detection levels of mature cathepsin K in 
this system compared to procathepsin K. 
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 Media levels of mature cathepsin K, and pro- and mature cathepsin S were highest 
in the experimental groups consisting of exclusively cathepsin K or cathepsin S 
overexpressing cells, respectively. Unexpectedly, media levels of procathepsin K were not 
significantly increased in the all cathepsin K cell group compared to the half cathepsin K 
and half wildtype group. The lack of an increase in procathepsin K upon doubling the CatK 
producing cells points to a nonlinear relationship between cathepsin K production and its 
accumulation in media. One potential explanation for this unusual relationship between K 
cells and CatK accumulation is mature cathepsin K cannibalizing procathepsin K, similarly 
to cannibalism by mature cathepsin S. 
 No significant differences in pro- or mature S and K were observed between lysate 
of CatS+CatK and wt+CatK cells, suggesting cathepsins were not endocytosed, or that 
endocytosed cathepsins do not significantly impact intracellular cathepsin levels in these 
cells. HEK293T cells are not known to be exceptionally endocytic and intracellular 
cannibalism caused by endocytosis is more likely to occur in highly endocytic cells such 
as macrophages. Intracellular pro and mature cathepsins K and S all increased when 
wildtype cells were replaced with cells producing the same cathepsin (CatK+CatK and 
CatS+CatS), suggesting any possible cathepsin K autodigestion has a minimal intracellular 
impact in these engineered cells. 
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Figure 4-2: Media procathepsin K is significantly decreased when cocultured with 
cathepsin S producing cells. HEK293T cells were stably DNA transfected with plasmids 
to constitutively overexpress cathepsins K or S. Equal numbers of different combinations 
of cells were seeded, then switched to serum-free media for 24 hours. Lysate and 
conditioned media were collected and media was concentrated 10-fold using acetone 
precipitation then equal amounts of protein were analyzed by Western blot. Procathepsin 
K was significantly lower in media collected from cathepsin S and K cocultured cells 
(CatS+CatK) compared to K cells cocultured with wildtype cells (wt+CatK). Procathepsin 
K was not significantly increased when K cells filled the entire plate (CatK+CatK) 
compared to when half the plate was seeded with wildtype cells (CatK+wt). mature K, 
procathepsin S and mature S in the media and procathepsin K, mature K, procathepsin S 
and mature S had no significant difference between cathepsin K and S coculture compared 

























































































































































cells were replaced with more cathepsin overexpressors of the same type (n=3, * p < 0.05 
by two tailed t-test). 
4.3.3 Development of a mathematical model of cathepsin S and K dynamics in 
cellular coculture system 
 A mathematical model of cathepsin S and K overexpressing cells in coculture was 
constructed to explore possible cannibalistic interactions. Model interactions were 
implemented based on the diagram in Figure 4-3 and the mathematical representation is 
detailed in Methods. Cathepsin S and K cells are represented by independent variables, 
allowing the model to simulate the different coculture scenarios in Figure 4-2. 
Procathepsins S and K are secreted linearly, influenced by the amount of CatS or CatK 
cells in the system. Procathepsins are then activated to mature forms and degraded linearly. 
Mature cathepsins S and K are able to bind and degrade pro- and mature cathepsin K by 
forming complexes and degrading the enzymes according to enzyme-specific kinetic rates. 
 The model does not explicitly include cell growth, assuming rates of cell growth 
between S and K cells are similar over a 24-hour culture period. We assume cathepsins S 
kinetic rates (binding, unbinding and catalysis) on pro- and mature cathepsin K are 
equivalent, since the likely binding sites for cathepsin S on cathepsin K identified 
previously are unlikely to be affected by procathepsin K’s propeptide [108]. Similarly, we 
assume the rates for cathepsin K binding and degrading procathepsin K are equivalent to 





Figure 4-3: Model diagram for cathepsin S and K producing cells in coculture. S and K 
cells are modeled as independent variables secreting procathepsin S (ProS) and 
procathepsin K (ProK), which are activated to mature S (MatS) and mature K (MatK). 
MatS is able to bind and degrade both ProK and MatK. MatK is also able to bind ProK and 
MatK and degrade them as well. 
 
4.3.4 Repeated parameter estimation yields four distinct families of solutions 
representing different degradation scenarios 
 The model was fit to a combination of the 24-hour data and time courses measuring 
media cathepsin accumulation by cathepsin overexpressing cells as described in Methods. 
To investigate the relative contributions of cathepsins S and K to cathepsin degradation, 
the 12 model parameters were estimated 100 times using COPASI’s built-in genetic 
algorithm with a population size of 10,000 for 200 generations, requiring 2 million function 
evaluations per run (See Appendix 2 for parameter estimation details). Some parameters, 
































displayed little variation across the estimated solutions (Figure 4-4A). However, there was 
a much wider range of estimated values for the enzyme kinetic rates governing the binding 
and catalysis of cathepsin S on K cannibalism and cathepsin K autodegradation.  
 The estimated parameter sets were organized by hierarchical distance clustering, 
revealing 4 distinct families of solutions, red, cyan, green and blue (Figure 4-4B). A log 
scale heatmap of the parameter sets reveals that cathepsin K and S secretion rates are 
extremely similar across all solutions, along with CatS activation and CatS degradation 
(Figure 4-4B). Cathepsin K activation rate is consistently lower in the blue cluster 
compared to the red and green clusters indicating that the activation rate could be a pivotal 
difference in the behavior of these two clusters. Interestingly, cathepsin K degradation (not 
caused by K or S cannibalizing K) is extremely consistent among the red and green clusters, 
while it is much more varied among the blue cluster. Consistently high CatK activation and 
degradation rates in the green and red clusters suggests cathepsin K is being rapidly 
activated and degraded, likely without being proteolyzed by itself or cathepsin S. 




Figure 4-4: Repeated parameter estimation yields four distinct families of solutions.  
Parameters were estimated by genetic algorithm 100 times and the resulting parameter 
values were graphed by box plot (A). Estimated parameters were compared by hierarchical 
clustering and divided into four solution families and the values of parameters in those 
families were examined by heat map (B). 
 
 Simulations using the estimated parameters confirmed that the red and green 
solutions predicted much more cathepsin K activation and non-cathepsin mediated 
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cathepsin K degradation than the blue or cyan solutions (Figure 4-5A). Predicting high 
non-cathepsin mediated cathepsin K degradation is at odds with the experimental results 
shown in Figure 4-2, where adding cathepsin S producing cells significantly decreased 
media procathepsin K. The families of solutions were also analyzed based on the catalytic 
efficiency of cathepsin K degradation they predicted by cathepsins S and K. Kinetic 
parameters were calculated for each solution where: 
 
  𝐾U =	
(IWXXYI+34)
IW[




 Solutions were graphed according to predicted catalytic efficiency of cathepsin S 
on cathepsin K cannibalism against cathepsin K autodegradation (Figure 4-5B). Cathepsin 
K catalytic efficiency was considerably higher in the blue and cyan solutions, meaning 
cathepsin K autodegradation is more rapid in these solutions compared to the red and green 
parameter sets. The contribution of cathepsin S to cathepsin K degradation was less clearly 
delineated, with some red and blue solutions predicting low or high catalytic efficiency, 
while green and cyan solutions predicted a greater contribution of cathepsin S. These 
estimated parameter sets contained a large number of solutions that predicted cathepsins 
were minimally involved in cathepsin degradation (red and green clusters). Analysis of the 
clustered parameter heatmap revealed these solutions were characterized by high cathepsin 
K activation rates, which resulted in the high cathepsin K activation and subsequent non-
cathepsin mediated cathepsin K degradation we observed in simulations.  
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Figure 4-5: Parameter solution families predict different degrees of cathepsin involvement 
in cathepsin K degradation. Time course results were simulated for each family of solutions 
and the amount of cathepsin K activation, and non-cathepsin mediated cathepsin K 
degradation were graphed. The red and green solutions predicted much larger cathepsin K 
activation and non-cathepsin mediated degradation than the blue or cyan solutions (A). 
Parameter solution families predict different catalytic efficiency of cathepsin K on 
cathepsin K and cathepsin S on cathepsin K. The catalytic efficiency of each solution was 
plotted and red and green solutions were found to predict low cathepsin K on cathepsin K 
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catalytic efficiency, while blue and cyan solutions predicted high cathepsin K on cathepsin 
K catalytic efficiency (B).  
4.3.5 Restricting parameter space through cathepsin K activation yields solutions 
which predict cathepsin involvement in cathepsin degradation 
 To better identify solutions capable of explaining the relative contributions of 
cathepsins S and K to cathepsin K cannibalism, we refined our parameter estimation 
bounds by lowering the upper limit of the cathepsin K activation rate and repeated the 
parameter estimation. Analysis of the catalytic efficiencies of the new parameter sets 
revealed three main solution families, CatK dominant, equal partners and CatS featured 
(Figure 4-6). Notably, all of the refined parameter solutions predicted cathepsin 
degradation was influenced by cathepsins, agreeing with experimental observations. 
However, these solutions differ in their predicted contributions of cathepsins S and K to 
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Figure 4-6: Restricting parameter estimation space yields three new solution families.  
Parameter estimation was repeated after lowering the bounds on cathepsin K activation 
rate, which was found to be high among solutions predicting little cathepsin involvement 
in cathepsin degradation. The refined parameter estimation yielded CatK Dominant, Equal 
Partners and CatS Featured solutions, which could be differentiated based on catalytic 
efficiency of cathepsins S and K on degrading cathepsin K. 
 
 Each solution was simulated to show predicted procathepsin K degradation when 
cathepsin S and cathepsin K overexpressing cells are cocultured. The CatS featured 
solutions (red) predict the least degradation of procathepsin K by cathepsin K, and predict 
roughly the same degradation of procathepsin K by cathepsins K and S (Figure 4-7A). The 
CatS featured solutions are also quite internally consistent, with most of the simulations 
among this group predicting very similar behavior. In contrast, the CatK dominant and 
equal partners solutions predict a wider range of possible procathepsin K degradation, but 
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in general they predict more involvement of cathepsin K than cathepsin S in procathepsin 
K degradation. 
 All three solution families fit the 24-hour time course data similarly well, but the 
solutions predicted drastically different behavior for time points outside the experimental 
time course (Figure 4-7B). CatS featured predictions were again quite internally consistent 
and display far less volatility and oscillatory behavior than CatK dominant or equal partners 
solutions. Interestingly, the CatS featured solutions reach a reasonable steady state even 
when cathepsin S producing cells are not present in the system. When cathepsin S cells are 
added to the system, the amount of procathepsin K continues to decrease over time as the 
total cathepsin S accumulates in the media. While oscillatory behavior is possible in the 
system, the extreme rises and falls predicted by the CatK dominant solutions are unlikely 
to occur biologically. 
 Despite the consistency in the CatS featured predictions and the similar catalytic 
efficiencies predicted in this group shown in Figure 4-6, there are a range of enzyme kinetic 
parameters observed among these solutions. A box plot of all of the refined solutions (CatK 
dominant, equal partners and CatS featured) shows there is still considerable variation 
among solutions, particularly in enzyme kinetic rates (Figure 4-8A). CatS featured 
solutions restrict these ranges somewhat, particularly among the on rates for cathepsins S 
and K binding to cathepsin K (Figure 4-8B). However, off and catalytic rates retain a great 





Figure 4-7: CatS featured parameters are more consistent and less volatile than other 
solutions.  
Model time course simulations were generated for each of the refined solutions. CatS 
featured solutions (red) predicted lower contributions of cathepsin K, and higher 
contributions of cathepsin S, to procathepsin K degradation compared to the CatK 
dominant (blue) and equal partners (green) solutions (A). All solutions fit the time course 
data similarly over 24 hours, but different parameter sets predicted very different dynamic 
behavior once the 24 hour time course ended (B). Most CatS featured solutions were tightly 
grouped, changing gradually at the end of the time course. The CatK dominant and equal 





Figure 4-8: CatS featured solutions have consistent kinetic on rates.  
The values of parameters among the refined solutions (A) and CatS featured solutions (B) 
were examined by box plot. CatS featured solutions displayed less variance than the 
combination of all refined solutions, most notably among on rates for cathepsins K and S 
binding to cathepsin S. 
 
4.3.6 Incubation with cathepsin inhibitors increases procathepsin K accumulation 
in conditioned media of macrophages cocultured with cathepsin 
overexpressing cells 
 To test whether cathepsins produced by macrophages are capable of cannibalizing 
cathepsin K, Thp-1 human macrophages were cocultured with cathepsin K overexpressing 
 54 
cells. Cells were treated with the cathepsin inhibitor E64 and transfected with mRNA for 
the endogenous protein inhibitor of cathepsins, cystatin C, which is constitutively secreted 
by most human cells. Treating cells with E64 was found to increase media procathepsin K 
compared to vehicle treatment, consistent with E64 preventing cathepsin S and cathepsin 
K degradation of procathepsin K (Figure 4-9). Cystatin C mRNA did not affect level of 
procathepsin K in the conditioned media, but it did significantly decrease the level of 
procathepsin S detected in conditioned media (Figure 4-9B). Cystatin C mRNA was 




Figure 4-9: E64 prevents degradation of media procathepsin K when macrophages are 
cocultured with K+ cells.  
Thp-1 macrophages were cocultured with wildtype or cathepsin K producing HEK cells, 
then treated with cystatin C mRNA or E64. Conditioned media were collected after 24 
hours and cathepsin K, cathepsin S and cystatin C were measured by Western blot (A) and 
quantified by densitometry (B). Procathepsin K was significantly increased following E64 
treatment, while cystatin C mRNA had no effect on cathepsin K levels. Cystatin C 
significantly decreased procathepsin S in media from wildtype and cathepsin K 
overexpressing cells, and E64 had no effect on cathepsin S levels. Probing for cystatin C 
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confirmed cystatin C mRNA transfection induces cystatin C overexpression (n = 3, * p < 
0.05 by t-test). 
 
 Lysate from the macrophage-HEK293T cocultures was probed for cathepsins K 
and S and cystatin C to evaluate the effects of inhibitor treatment and mRNA transfection 
on intracellular protein levels (Figure 4-10). Cathepsin K did not appear to change under 
any treatment conditions. Interestingly, pro- and mature cathepsin S was almost 
undetectable following cystatin C transfection but appeared unaffected by E64 treatment. 
Cystatin C mRNA was again confirmed to increase cystatin C expression, where the 
protein was only detectable in lysate from mRNA transfected cells. Additional experiments 
using different concentration methods and carboxymethyl papain to compete with cystatin 
C, were conducted and shown in Appendix 5. 
 
Figure 4-10: Transfection with cystatin C mRNA decreases cathepsin S in macrophage 
lysate. Thp-1 macrophages were cocultured with wildtype or cathepsin K producing HEK 
cells, then treated with cystatin C mRNA or E64. Cells were lysed after 24 hours and 
cathepsin K, cathepsin S and cystatin C were measured by Western blot. Pro- and mature 
cathepsin S levels were decreased following cystatin C mRNA treatment, while E64 had 
no effect on cathepsins S or K in lysate. Cystatin C was detectable in the lysate of cystatin 
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C mRNA treated cells, while cystatin C was undetectable in cells not transfected with 
mRNA. 
4.4 Discussion 
 We sought to investigate the effects of cathepsin cannibalism in multicellular 
systems where it regulates proteolysis through the controlled degradation of proteases. We 
showed that cathepsin cannibalism between recombinant cathepsins S and K likely occurs 
in cell culture media, and in an engineered cellular system. Using mathematical modeling 
techniques we identified ranges of likely kinetic rates for cathepsin cannibalism, predicting 
that in the extracellular environment, cathepsin S on cathepsin K cannibalism proceeds 
more rapidly than cathepsin K autodegradation. We also demonstrated that cathepsin 
cannibalism occurs in a macrophage coculture system and it can be prevented using 
cathepsin inhibitors. These results provide further evidence that cathepsin cannibalism and 
autodegradation are physiologic regulatory processes which can occur in the shared 
extracellular spaces of cells producing these proteases, and that this regulation could be 
disrupted by treatment with cathepsin inhibitors potentially causing unexpected side effects 
including increases in cathepsins. 
 We first established that cathepsin cannibalism between cathepsins S and K can 
occur in the presumed neutral pH environment of cell culture media. We found cathepsin 
S was considerably more active than cathepsin K under these conditions, and that when 
coincubated together cathepsins K and S hydrolyze less of the fluorogenic substrate than 
would be predicted by adding the outputs of the two enzymes together (Figure 4-1). Next, 
we created an experimental model of macrophage and breast cancer cell cathepsin 
dynamics using HEK293T cells engineered to overexpress cathepsins S and K. We found 
coincubation of cathepsin K and S producing cells decreased procathepsin K in the cell 
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culture media, supporting the existence of cathepsin cannibalism in cellular systems 
(Figure 4-2). We also observed doubling the concentration of cathepsin K producing cells 
did not significantly increase the procathepsin K concentration in the media, suggesting a 
nonlinear relationship between cathepsin K production and accumulation, hypothesized to 
be caused by autocatalysis of cathepsin K by itself.  
 We created a computational model of cathepsin S and K coculture to examine the 
differences in degradation of cathepsin K by itself compared to degradation by cathepsin 
S (Figure 4-3). We parameterized the model to time course data, generating four distinct 
families of solutions through hierarchical clustering, each predicting different contributions 
of cathepsin K and cathepsin S to the degradation of cathepsin K (Figure 4-4). Many of 
these initial solutions predicted cathepsins were not responsible for significant cathepsin K 
degradation, a prediction in conflict with the experimental evidence (Figure 4-5). We were 
able to refine our solutions by restricting the values of cathepsin K activation, resulting in 
a set of refined solutions (CatK dominant, equal partners and CatS featured) that predicted 
different contributions of cathepsins to cathepsin K degradation (Figure 4-6). CatS featured 
solutions generated the most consistent and least volatile predictions, providing evidence 
for their validity in explaining the biological system (Figure 4-7). 
 To demonstrate that cathepsin cannibalism can occur with the involvement of 
macrophages, Thp-1 macrophages were cocultured with cathepsin K overexpressing cells 
and cathepsin degradation was inhibited with E64 and cystatin C overexpression. E64 
increased procathepsin K, consistent with inhibition of cathepsins preventing cathepsin 
cannibalism (Figure 4-9). However, cystatin C mRNA transfection did not affect cathepsin 
K in the media but did decrease cathepsin S in the media and lysate of cocultured cells 
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(Figure 4-10). This decrease in lysate cathepsin S following cystatin C mRNA transfection 
could be evidence for a regulatory mechanism controlling cathepsin S production 
modulated by cystatin C levels. Additional experiments measuring cathepsin S protein and 
mRNA levels, utilizing recombinant cystatin C and different dosages of cystatin C mRNA 
will need to be conducted to determine the cause of this surprising decrease in lysate 
cathepsin S following cystatin C mRNA transfection.  
 The primary goal of representing the cathepsin coculture system mathematically 
was parsing the relative contributions of cathepsins S and K to cathepsin K degradation. 
Through multiple rounds of parameter estimation and refinement, we were able to arrive 
at a family of solutions that predict cathepsin S degrades cathepsin K with somewhat more 
rapid kinetics than it degrades itself. We were also able to derive some other insights about 
the system through analyzing these parameters. Most of the solutions we generated 
predicted the secretion rate of cathepsin K as between 50-100% faster than cathepsin S 
secretion. This seems to likely be the case as media cathepsin K levels were generally 
higher than cathepsin S in spite of the hypothesized degradation of cathepsin K by itself 
and cathepsin S. Additionally, there was very little disagreement on secretion rates between 
the different parameter sets (Figure 4-4A and Figure 4-8A). Previous in vitro results 
suggest cathepsin K autodegradation could actually be faster than cathepsin S on K 
cannibalism (Ferrall-Fairbanks et al. in preparation). These in vitro experiments were 
conducted at pH 6, while cathepsin K is much less active in the slightly alkaline pH 
environment of cell culture media. However, a significant amount of enzyme degradation 
could be happening in the pericellular space, where the pH can be lower due to the secretion 





5 PERTURBATIONS TO CATHEPSIN PROTEOLYTIC 
NETWORKS WITH MOLECULAR APPROACHES 
5.1 Introduction 
 DNA transfection and the generation of stable cell lines are incredibly powerful 
techniques that have allowed us to generate experimental models of cathepsin 
overexpression (Chapter 4) and purify recombinant cathepsins from conditioned media 
(Chapter 6). However, DNA transfection is limited by its efficiency, particularly in primary 
cells, which do not readily express foreign DNA. To address this need we collaborated 
with the Santangelo Lab at Georgia Tech to produce a series of cathepsin and cystatin C 
specific mRNA suitable to induce overexpression in a variety of cell types with high 
efficiency [110]. Additionally, these cathepsin and cystatin mRNA could be used to probe 
for possible regulatory connections between different cathepsin family members, where 
the overexpression of one cathepsin could decrease the expression of another through 
digestion or potentially increase expression through stimulating transcription or inhibiting 
degradation of another cathepsin. 
5.2 Materials and Methods 
5.2.1 Development of cathepsin and cystatin C mRNA for overexpression 
 Overexpression mRNA coding for human wildtype cathepsins K, L, S and V, 
cystatin C and mutated cathepsin K was developed using methodology as previously 
described [111]. 
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5.2.2 Transfection of cells with cathepsin and cystatin C mRNA 
 HEK293T cells were grown to approximately 90% confluence on 12 well plates 
containing 1mL of DMEM (Lonza, supplemented with 10% FBS, 1% L-glutamine, 1% 
Penicillin/Streptomycin) before transfection. For each well, 4 µl of Lipofectamine 2000 
was diluted in 50 µl of Opti-MEM reduced serum media and 2 µg of mRNA was diluted 
in 50 µl of Opti-MEM. Diluted Lipofectamine 2000 and diluted mRNA were mixed in 
equal amounts then Lipofectamine 2000-mRNA complexes were allowed to form for 5 
minutes at room temperature. After incubation, 100 µl of complexes were added to each 
well for transfection. Cells were lysed after 12 hours and overexpression was assessed with 
Western blot and cathepsin zymography. 
5.2.3 Western blot  
 Western blot was used to measure mRNA induced protein overexpression. Total 
protein concentration in cell lysate was determined by BCA, then equal amounts of protein 
were mixed with reducing loading dye, briefly boiled, then loaded into 12.5% 
polyacrylamide gels and separated by electrophoresis. Proteins were transferred onto 
nitrocellulose membranes, blocked and probed with primary antibodies for human 
cathepsin S (R&D Systems), human cathepsin L (R&D Systems), human cathepsin 
V(R&D Systems), human cathepsin K (Proteintech) or human cystatin C (EMD Millipore). 
Membranes were probed with secondary antibodies (LI-COR) then imaged on a LI-COR 
Odyssey CLx Imaging System. 
5.2.4 Cathepsin zymography 
 Cathepsin zymography was used to measure active cathepsins in mRNA transfected 
cells as described previously [84, 85]. Briefly, equal amounts of protein were loaded in 
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12.5% polyacrylamide gels embedded with 0.2% gelatin and separated by electrophoresis 
at 4°C. Gels were washed in renaturing buffer and incubated in assay buffer overnight at 
27°C. Gels were stained with Coomassie blue, destained and imaged on an ImageQuant 
LAS 4000 (GE Healthcare).  
5.2.5 Measuring proteolysis with fluorescently quenched elastin 
 HEK293T cells were transfected with mRNA then after 4 hours cells were switched 
to media containing 0.05mg/ml DQ elastin. Samples of the media were taken after another 
4 and 20 hours, and fluorescence was quantified in a plate reader. Background fluorescence 
(measured with a media containing DQ Elastin control) was subtracted out of all reported 
measurements. 
5.3 Results 
5.3.1 Transfection with cathepsin mRNA induces overexpression in cells 
 Cathepsin K, L, S, V and cystatin C mRNA capable of inducing overexpression 
were developed to study cathepsin cannibalism in living cells. Additional mRNA for 
cannibalism resistant mutants of cathepsin K (KV171A, KL253V, KL253A) were developed 
according to predictive cleavage sites previously identified using the protease-on-protease 
predictive algorithm, PACMANS [108]. HEK293T cells were transfected with cathepsin 
and cystatin C mRNA and efficacy of overexpression was evaluated by Western blot 
(Figure 5-1). Procathepsins L, S and V and cystatin C were detectable in transfected lysate. 
Procathepsin KV171A and KL253V were also detectable by Western blot, however wildtype 
cathepsin K and KL253A were not. Mature cathepsin S and V were clearly detectable, but no 
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other mature cathepsins were detectable in mRNA transfected HEK293T cells, indicating 
the mRNA protein is not being activated properly in these cells.   
 MDA-MB-231 breast cancer cells were also transfected with cathepsin and cystatin 
C mRNA to determine the effectiveness of mRNA transfection in a cell type that expresses 
multiple cathepsins endogenously. We also wanted to test the hypothesis that 
overexpression of cellular cathepsins could affect the expression of other cathepsins.  
MDA-MB-231 cells were transfected, lysed and protein expression was evaluated by 
Western blot (Figure 5-2A). Endogenous procathepsin K, as well as pro and mature 
cathepsins L and S were detectable in all MDA-MB-231lysate. Similarly to HEK293T 
cells, overexpression of procathepsins L, S and V, KV171A and KL253V were detected in 
transfected MDA-MB-231cells.  Wildtype cathepsin K and KL253A were potentially 
increased following transfection, but to a lesser extent than KV171A and KL253V. Mature 
cathepsin S was increased following transfection, but no other mature cathepsins appeared 
elevated compared to control and vehicle treated cells. Procathepsin V appeared to be 
detectable in cells transfected with KV171A and KL253V mRNA, however a subsequent 
Western blot using recombinant K and lysate from engineered HEK293T cells that stably 
express cathepsin K, revealed the cross reactivity of the cathepsin V antibody used 
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Figure 5-1: mRNA transfected cells produce cathepsins S, L, V, cannibalism resistant mutants of 
cathepsin K and cystatin C. HEK29T were transfected with mRNA for cathepsins S, L, V, Kwt, 
KV171A, KL253V KL253A or cystatin C. After 12 hours, cells were lysed and equal amounts of protein 
were analyzed by Western blot. Transfected protein was clearly detectable in cells transfected 
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Figure 5-2: mRNA transfection is successful in breast cancer cells. MDA-MB-231 
breast cancer cells were transfected with cathepsin overexpression mRNA, lysed and 
equal amounts of protein were measured by Western blot (A). Procathepsin K was 
elevated in KV171A and KL253V, but not Kwt or KL253A, but no mature K was detectable 
in any lysate. Procathepsin L and procathepsin S were elevated in cells transfected with 
L and S mRNA, respectively. Procathepsin V appeared to be elevated in V, KV171A and 
KL253V mRNA transfected cells. Recombinant cathepsin K and lysate from HEK293TK+ 
cells shows the cathepsin V antibody cross reacts with cathepsin K. 
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5.3.2 mRNA transfection yields active cathepsin V and inhibitory cystatin C 
 To test whether mRNA transfection can produce active cathepsins capable of 
degrading substrate, mRNA transfected cells were lysed 12 and 24 hours post transfection 
and active cathepsins were assayed using cathepsin zymography (Figure 5-3). An active 
cathepsin V band was detectable in cells transfected with cathepsin V mRNA. Active 
cathepsin L bands were detectable in vehicle and mRNA transfected cells, though the 
active cathepsin L band was not increased in the cells transfected with L mRNA. No 
cathepsin S or cathepsin K bands were detectable by zymography. 
 To test whether mRNA transfected cells can secrete active cathepsins and inhibitory 
cystatin C, HEK293T cells were transfected with mRNA for cathepsin S, cystatin C or both 
cathepsin S and cystatin C, then switched to media containing 50µg/mL DQ Elastin after 
4 hours. Media was collected after another 4 and 20 hours, and fluorescence was 
immediately measured using a plate reader. Fluorescence was not increased in cells 
transfected with cathepsin S mRNA, suggesting transfected cells do not secrete 
catalytically active cathepsin S. However, cystatin C transfected cells had markedly 
decreased fluorescence compared to the other experimental groups after 20 hours, 
indicating cystatin C produced by transfected cells is capable of inhibiting proteolysis by 





Figure 5-3: mRNA transfected cells produce active cathepsin V as well as cystatin C 
capable of inhibiting elastin degradation. HEK293T cells were transfected with mRNA for 
cathepsins K, L S and V, lysed and equal amounts of protein were loaded for cathepsin 
zymography. Cathepsin V transfected cells produced an active band characteristic of 
cathepsin V. There was no difference in active cathepsins detected between K, L and S 
transfected cells compared to vehicle controls (A). HEK293T cells were transfected with 
cathepsin S, cystatin C or both cathepsin S and cystatin C mRNA. After 4 hours, cells were 
switched to media containing 50µg/mL DQ Elastin. Fluorescence in the conditioned media 
was measured after an additional 4 or 20 hours after the addition of DQ Elastin. Cells 
transfected with cathepsin S mRNA did not produce more fluorescence than untransfected 




 Cathepsin and cystatin C specific mRNA successfully induced overexpression of 
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detectable zymography signal, indicating the other overexpressed cathepsins were not 
catalytically active in transfected cells. Overexpressed cystatin C reduced elastinolysis in 
conditioned media from transfected cells, confirming its inhibitory potential. 
Overexpression of cathepsins in MDA-MB-231 breast cancer cells did not cause any 
changes in off-target cathepsins measured by Western blot. 
 Based on the success of most of the cathepsin mRNA in producing the target 
protein, we hypothesize that there is an issue with the cathepsin Kwt and KL253A mRNA, 
rather than a problem with the transfection protocol since the same procedure was used for 
all mRNA. Our collaborators in the Santangelo lab are producing new batches of these 
mRNA to determine if there was a problem when producing the previous batch.  
 Detecting active overexpressed cathepsins in only the cathepsin V mRNA 
transfected cells is surprising, since DNA transfection has previously yielded active 
cathepsins K, L, S and V in the same HEK cell line. Further experimental optimization is 
required to determine why cathepsins produced by these engineered mRNA are not 
catalytically active. Potential causes could include improper glycosylation of the 
procathepsins, failure to tag the cathepsins in the Golgi with mannose 6-phosphate, or 




6 PURIFICATION OF RECOMBINANT CATHEPSINS 
6.1 Introduction 
 Measuring the kinetics of cathepsin cannibalism presents a unique array of 
challenges compared to measuring more conventional enzyme substrate reactions. First, 
cathepsins are promiscuous proteases and cannibalistic interactions between two 
cathepsins can be bidirectional, requiring mutated versions of these enzymes that are 
resistant to cannibalism or unable to cleave substrates, including other cathepsins. 
Cathepsins also act as both the substrate and enzyme in these reactions, necessitating a 
larger amount of enzyme than would normally be required to measure kinetic rates. These 
challenges motivated the generation of plasmids for active site dead and cannibalism 
resistant mutant plasmids of cathepsins K, L and S and the generation of stable HEK293T 
cell lines that either express cathepsins constitutively with a cytomegalovirus promoter, or 
in response to tetracycline treatment due to repressor proteins inhibiting transcription 
[103].  
 The cathepsin plasmids also feature a 6x-Histidine tag (His-Tag), allowing for 
purification through immobilized metal ion affinity chromatography [112]. The His-Tag 
reversibly binds to nickel cations allowing for the removal of off-target proteins before 
eluting the target protein with an Imidazole buffer, which outcompetes for the His-Tag, 
releasing it from the nickel column. Optimizing a method for producing large amounts of 
recombinant wildtype and mutant cathepsins would allow for further investigations into 
the exact mechanisms of cathepsin cannibalism. 
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6.2 Materials and Methods 
6.2.1 Generation of cathepsin overexpressing cell lines 
 HEK293T cells were stably transfected with plasmids coding for 6x-Histidne 
tagged wildtype and mutant cathepsins as previously described [103]. HEK293T cells were 
transfected with linearized plasmids containing cathepsin S or cathepsin L DNA under 
control of a T-REx (Invitrogen) expression system consisting of a cytomegalovirus 
promotor controlled by two tetracycline repressor sites. Treatment with tetracycline 
releases repressor proteins from the repressor sites, allowing transcription to occur. 
6.2.2 Cell culture and media collection 
 HEK293TS+ and RAW264.7 cells were cultured in DMEM containing 10% FBS, 
1% L-Glutamine and 1% Penicillin Streptomycin. Cathepsin S overexpression was induced 
in HEK293TS+ cells by adding tetracycline to the culture media for 6 hours before changing 
the cells to serum-free media also containing tetracycline for an additional 24 hours. 
Conditioned serum-free media was collected from RAW264.7 cells after 24 hours.    
6.2.3 Nickel chelating resin protein purification 
 G Biosciences Nickel Chelating Resin was used to purify 6x-Histidine tagged 
cathepsins from conditioned media and lysate of cathepsin overexpressing HEK293T cells 
according to the manufacturer’s protocol for native proteins. Resin was washed with water 
and binding buffer in a spin column before incubation with media or lysate for 60 minutes 
at 4°C. Resin was collected in a spin column, washed with wash buffer and then target 
proteins were eluted in multiple fractions with an elution buffer containing 250mM 
Imidazole.  
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6.2.4 Western blot and SDS-PAGE 
 Equal volumes of purified media samples were mixed with reducing SDS-PAGE 
loading buffer, briefly boiled, loaded and separated on 12.5% polyacrylamide gels. For 
Western blots, proteins were transferred to nitrocellulose membranes, blocked then probed 
with primary antibodies for cathepsin S (R&D Systems), 6x-His tag (Invitrogen) or 
cathepsin L (R&D Systems). For SDS-PAGE, gels were stained with Coomassie Blue and 
destained. 
6.2.5 Multiplex Cathepsin Zymography 
 Equal volumes of purified media samples were mixed with nonreducing SDS-
PAGE loading buffer and cathepsin zymography was performed as previously described 
[72, 73]. 
6.2.6 Cathepsin Activation 
 Cathepsins in conditioned media were activated through incubation in an assay 
buffer containing 20mM sodium citrate, 10mM dithiothreitol, 25 µg/ml dextran sulfate, pH 
4.6 at 37°C [113]. 
6.2.7 Desalting 
 Samples were desalted using a Zeba Spin Desalting Column (7kDA MWCO, 
10mL, ThermoFisher Scientific) according to manufacturer’s recommendations. The 
desalting column was washed with water, then samples were loaded and recovered via 





Figure 6-1: Overview of protein purification process from cathepsin overexpressing cells. 
HEK293T cells were previously transfected with a 6xHistidine human cathepsin S plasmid 
containing tetracycline repressor sequences. Cells were stimulated with tetracycline for 6 
hours in complete medium (A) before being switched to serum-free media containing 
tetracycline (B). Conditioned serum-free media was collected after 24 hours (C), run 
through a nickel resin column, and purified proteins were eluted in fractions using 
imidazole (D). Purification was validated using SDS-PAGE, Western blot and cathepsin 
zymography (E). 
6.3.1 Purification of cathepsin S using nickel chelating resin 
 Engineered HEK293T cells were grown to confluence in two 15cm cell culture 
dishes. Cathepsin S expression was induced by adding tetracycline to the culture media for 
six hours before switching the cells to serum-free media containing tetracycline for an 
additional 24 hours (Figure 6-1). After 24 hours, media and lysate were collected and 
purified using 1 mL of nickel chelating resin in a spin column and analyzed using Western 
blot (Figure 6-2A) and SDS-PAGE (Figure 6-2B). Pro and mature cathepsin S bands were 
clearly detectable in the unpurified lysate and lysate runoff, indicating very little of the 
target protein was purified by the column. Faint procathepsin S bands in the lysate fractions 
are further evidence of the poor purification from cell lysate. Clear pro and mature 
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cathepsin S bands were clearly detectable in the media purification fractions, indicating a 
much more effective purification from the conditioned media compared to cell lysate. The 
vast majority of the purified enzyme was found in the first 3 elution fractions. A faint 
procathepsin S band was also detectable in the media runoff, indicating that 1 mL of nickel 
chelating resin was insufficient to capture all of the cathepsins in the cell culture media. 
SDS-PAGE revealed a 37 kDa band characteristic of procathepsin S in the first purified 
media fraction. The presence of multiple bands in the media runoff, but only a band at 37 
kDa in the media fraction suggests the purification successfully removed the off-target 
proteins from the sample.   
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Figure 6-2: Purified pro and mature cathepsin S is detectable in media elution fractions. 
Cell lysate and conditioned media were collected from tetracycline induced cathepsin S 
overexpressing HEK293T cells, purified on a nickel resin column, eluted with 250mM 
imidazole buffer five times and analyzed by Western Blot (A) and SDS-PAGE (B). Pro 
and mature cathepsin S was detectable in the unpurified lysate and lysate runoff. 
Procathepsin S was weakly detected in only the first lysate elution fraction. Pro and mature 
cathepsin S were detectable in the first four elution fractions, and procathepsin S was 
weakly detectable in the media runoff. SDS-PAGE detected multiple bands in the media 
runoff, the strongest at 75 kDa and 37 and 25 kDa bands in the first media fraction elution, 
characteristic of pro and mature cathepsin S, respectively. 
 
 Presence of the His-Tag, and absence of cathepsin L, in the purified samples was 
confirmed by Western blot (Figure 6-3). In the first two purified fractions, strong His-Tag 






RunoffL1 L2 L4L3 L5 M1 M2 M4M3 M5
Media
Runoff










Runoff L1 L2 L4L3 L5 M1 M2 M4M3 M5
Media
Runoff


















cathepsin S, respectively. 37 kDa bands were also detectable in the lysate, first purified 
lysate fraction and media runoff, indicating again that lysate purification is ineffective, and 
a greater volume of nickel resin is required to capture all of the cathepsin S produced in 
the media. Cathepsin L has previously been detected in HEK293T cells. Due to the similar 
protein structure and function between cathepsins S and L, we wanted to confirm none of 
the purified media samples contained cathepsin L. Purified media samples were analyzed 
by Western blot, probing with an antibody for human cathepsin L. Cathepsin L was 
detectable in the recombinant control, but not in any lysate or media samples.  
 
Figure 6-3: Purified cathepsin S is 6x-His tagged and no cathepsin L is present in the 
purified media. Cell lysate and conditioned media from cathepsin S overexpressing cells 
were collected and analyzed by Western blot. An antibody for 6x-Histidine revealed strong 
bands at 37 and 25 kDa, consistent with pro and mature cathepsin S. Cathepsin L was 
undetectable in the cell lysate and media before and after purification. 
 
 To assess whether the purified cathepsins were active and capable of degrading 
substrate, purified fractions were analyzed with cathepsin zymography (Figure 6-4). 
Multiple strong bands were detectable in the unpurified lysate, but in no other runoff or 
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purified fraction. A lack of zymography signal in any of the purified samples, despite 
Western detectable mature cathepsin S bands, suggests the purification process inactivates 
mature cathepsins, preventing them from degrading substrate following purification. 
   
 
Figure 6-4: Purified cathepsin S is not catalytically active. Cell lysate and conditioned 
media from cathepsin S overexpressing cells were collected and analyzed by multiplex 
cathepsin zymography. Strong active bands were detectable in the lysate of cathepsin S 
overexpressing cells, but no bands were visible in any of the purified fractions or runoff.  
 
 Purification from HEK293T cells overexpressing His-Tag cathepsins L and K were 
also attempted. Cathepsin L was successfully purified from the cell media and analyzed by 
Western blot (Figure 6-5). Strong procathepsin L bands were detectable in the purification 
fractions, though the presence of procathepsin L in the media runoff suggests a greater 
volume of nickel resin should be used when purifying cathepsin L. Cathepsin K was 
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Figure 6-5: Cathepsin L is detectable in purified media samples. Cell lysate and 
conditioned media were collected from tetracycline induced cathepsin L overexpressing 
HEK293T cells, purified on a nickel resin column, eluted with 250mM imidazole buffer 
three times and analyzed by Western Blot. Procathepsin L was clearly detectable in the cell 
lysate, all three purification fractions and media runoff. Double chain and mature cathepsin 
L were detectable in cell lysate but not in the media fractions or runoff. 
 
6.3.2 Attempted activation of purified cathepsin S acidic dextran sulfate buffer 
 Cathepsins are better able to tolerate neutral pH in their unactivated proforms than 
in their mature forms, following propeptide cleavage [114]. While cathepsin S is better 
able to retain its structure and activity at neutral pH than cathepsins L or K, the lack of 
detectable zymography signal indicates that some combination of factors during the 
purification process rendered the Western detectable mature cathepsin S in the purified 
media inactive. Cathepsin S activation proceeds much more quickly in an environment 
mimicking its physiologic endolysosomal niche, namely low pH and reducing environment 
[29]. Multiple activation protocols, including pepsin mediated activation and incubation at 
acidic pH in the presence of dextran sulfate, were tested on the purified cathepsin S 
samples, but none were able to generate zymography detectable active cathepsin S (not 















 The elution buffer used has a high salt concentration (500 mM NaCl). The high 
ionic strength of this solution could be inhibiting the autocatalytic and protein-protein 
binding events necessary for successful activation of cathepsin S. Purified media from 
cathepsin S HEKs was desalted by flowing through a Zeba spin desalting column and 
samples were analyzed by Western blot (Figure 6-6). Procathepsin S was faintly detectable 
in purified samples that were not desalted, and samples desalted then activated for 0 or 30 
minutes. No mature cathepsin S was detectable in any of the media samples (Figure 6-6A). 
Desalted samples were centrifugally concentrated approximately 20-fold then mixed 1:1 
with 2x activation buffer and analyzed by Western blot (Figure 6-6B). Pro and mature 
cathepsin S bands were clearly detectable in the lysate, unactivated and activated samples. 
However, there was no conversion from pro to mature cathepsin S over 5 minutes in 
activation buffer. Additional experiments found no zymography detectable cathepsins after 
5 or 30 minutes, and no increase in mature cathepsin S after 30 minutes of activation (data 
not shown).  
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Figure 6-6: Desalting media from cathepsin overexpressing cells does not affect activation. 
Conditioned media from HEK293TS+ cells was purified and desalted prior to incubation 
with cathepsin activation buffer and analyzed by Western blot (A). Procathepsin S was 
faintly detectable prior to desalting and undetectable by 60 minutes, with no mature 
cathepsin S detectable at any time point. Purified media was centrifugally concentrated 
prior to desalting and activation and analyzed by Western bot (B). Pro and mature cathepsin 
S were detected in the desalted and activated media. However, no significant transition 
from pro to mature cathepsin S was detectable in 5 minutes. 
 
 To determine which activation protocols can successfully activate cathepsins 
secreted in media, conditioned media was collected from RAW264.7 macrophages, a 
murine cell line that produces large amounts of cathepsins, and cathepsin S overexpressing 
cells. Pepsin mediated activation was not able to generate zymography detectable 
cathepsins in either RAW or HEK samples. Incubation in pH 4.6 citrate buffer containing 
25 µg/ml dextran sulfate greatly increased detectable active cathepsins after 30 minutes of 
incubation at 37°C (Figure 6-7). In contrast, cathepsin S overexpressing HEK media 
showed no increase in active cathepsins following incubation in the same buffer, 
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macrophage cathepsins, requiring the optimization of a new activation protocol for 
cathepsin S secreted by engineered HEK cells. 
 
Figure 6-7: Cathepsin activation buffer incubation increases active cathepsin S in media 
from RAW264.7 cells, but not from cathepsin overexpressing cells. Conditioned media 
was collected from RAW264.7 (A) and HEK293TS+ (B) cells and incubated with a 
cathepsin activation buffer for up to 120 minutes at 37°C. Prior to activation, no active 
cathepsins were detectable in RAW264.7 media. After 30 minutes of incubation, a strong 
active cathepsin S band was detectable, and persisted through 60 and 120 minutes. 
Conditioned media from the HEK293TS+ cells produced no active bands regardless of 
activation time.  
6.4 Discussion 
 Procathepsins S and L were successfully purified from conditioned media of 
engineered HEK293T cells using immobilized metal chromatography, moving the lab 
closer to in-house production of custom cathepsin mutants. No off-target proteins were 
detectable in the purified fractions, suggesting the protocol effectively concentrates only 
the target recombinant proteins. However, the resulting purified cathepsin was not 
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catalytically active, and attempts to activate the procathepsins through incubation in acidic 
buffers containing other proteases or dextran sulfate were unsuccessful, limiting the 
experimental usefulness of the purified enzyme. Despite high intracellular concentrations 
of the target cathepsins, purification from cell lysate was shown to be ineffective, likely 
due to the large amount of off-target proteins in cell lysate compared to media.  
 Development of a protocol to produce, purify and activate recombinant wildtype 
and mutant cathepsins would facilitate kinetic experiments to unravel the exact 
mechanisms at play during cathepsin cannibalism. Successful production of active site 
dead and cannibalism resistant mutants is necessary to measure cannibalism parameters 
accurately because cannibalism is a dynamic process where both enzymes have the 
potential to act on the other as substrate. Active site mutants reduce this complexity because 
they would strictly act as substrates for other cathepsins. Cannibalism resistant mutants can 
similarly be used to measure rates of cannibalism while also providing evidence for the 








7 DYNAMIC MODEL OF PROTEASE STATE AND INHIBITOR 
TRAFFICKING TO PREDICT PROTEASE ACTIVITY IN 
BREAST CANCER CELLS 
7.1   Introduction 
Recent advances in breast cancer treatment have drastically increased survival rates 
for early stage cancer patients, but metastatic stage 4 breast cancer remains extremely 
difficult to treat with a 5-year survival rate of only 22 percent [116]. Cysteine cathepsins 
have been implicated in cancer, with recent research revealing integral roles of cysteine 
cathepsins in promoting tumor growth and metastasis [26, 42]. Cysteine cathepsins are 
attractive pharmaceutical targets for the prevention of tumor metastasis since they not only 
are produced by the cancer cells themselves, but also participate in the accessory stromal 
cells of the tumors and the secondary metastatic sites, as with bone metastases. While some 
cathepsin inhibitors have shown efficacy in treating bone metastases, to-date, no cathepsin 
inhibitors have been approved for clinical use due to side effects, particularly skin lesions 
[43, 44]. The mechanisms responsible for these side effects are unknown, but could include 
inhibition of off-target proteases, inhibition in off-target tissues, or disruption of proteolytic 
networks necessary for normal cathepsin regulation. 
Cathepsin expression and activity is regulated by a complex proteolytic network 
consisting of a wide variety of proteases, specific endogenous inhibitors and biological 
substrates [30]. Cathepsins are translated as inactive procathepsins, which must be cleaved, 
either autocatalytically or by another protease, before they can become active mature 
enzymes capable of degrading substrates18,37. Changes to the localization, expression or 
activity of the proteases responsible for cleaving procathepsins can prevent or stimulate 
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cathepsin activity. Cathepsins and other proteases are also capable of degrading mature 
enzymes, preventing them from degrading substrates. We have previously reported that 
cathepsin S is capable of degrading cathepsin K, even in the presence of extracellular 
matrix substrates, resulting in an overall decrease in collagen proteolysis [70]. Given the 
contrary ability of proteases to both increase and decrease the activity of other proteases, 
it is unsurprising that inhibiting a single protease can cause unexpected side effects in 
clinical trials and in laboratory settings.  
 While pharmaceutical cathepsin inhibitors display strong, nanomolar enzyme 
specificity in vitro, inhibitor specificity can decrease substantially in intracellular 
environments. Many early cathepsin inhibitors were lysosomotropic, weakly basic, 
lipophilic molecules capable of passing through lipid membranes until they are protonated 
in acidic compartments such as the lysosome [117]. Lysosomotropic inhibitors, such as 
balicatib, have shown high intracellular potency, but poor specificity, preventing them 
from passing clinical trials [118, 119]. Emerging non-basic, non-lysosomotropic cathepsin 
inhibitors have shown improved in vivo selectivity and efficacy in clinical trials for 
osteoporosis and metabolic bone disease, but even these more specific inhibitors have 
resulted in unexplained side effects in patients [32].  
Unravelling the specific interactions of this network is difficult with only 
experimental methods due to the number of molecules involved and limitations of tracking 
specific molecules intracellularly. Mathematical modeling of cathepsin kinetics has been 
instrumental in characterizing the unique responses of recombinant proteins to substrates 
and inhibitors in vitro [64, 65].  
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This study seeks to uncover the post-translational regulatory mechanisms 
responsible for the previously observed increase in active cathepsin S following cathepsin 
inhibitor treatment in breast cancer cells. Additionally, this work expands the focus from 
the MDA-MB-231 triple-negative breast cancer cell line, to other breast cancer and 
macrophage cell lines, as well as primary human tumor and patient-matched normal tissue. 
This work utilizes a combination of experimental and mathematical modeling approaches 
to explore the mechanism responsible for previously observed increase in active cathepsins 
following cathepsin inhibitor treatment. The development of accurate mathematical 
cathepsin-inhibitor models will be instrumental to designing cathepsin inhibitor regimens 
capable of suppressing tumor growth and metastasis in breast cancer patients. 
7.2   Materials and Methods 
7.2.1 Cell culture 
 MDA-MB-231, MCF-7, and MCF-10A cells were incubated in DMEM (Lonza) 
medium with 10% FBS, 1% l-glutamine, and 1% non-essential amino acids and at 37°C 
with 5% CO2. Thp-1 macrophages were derived from Thp-1 monocytes cultured in RPMI-
1640 (Lonza) medium with 10% FBS, 1% L-glutamine and 1% Penicillin-Streptomycin. 
Thp-1 monocytes were differentiated into macrophages by treatment with 0.1uM phorbol 
12-myristate 13-acetate (PMA) for 24 hours, followed by 24 hours in fresh medium without 
PMA before E64 (trans-Epoxysuccinyl-L-leucylamido(4-guanidino)butane) treatment. 
7.2.2 Human tissue 
 Human cancer and normal breast tissue specimens were from National Disease 
Research Interchange (Philadelphia, PA). 
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7.2.3 Multiplex Cathepsin Zymography 
 Total protein concentration of cell lysate and homogenized tissue was 
measured using the Pierce Micro BCA Protein Assay (Thermo Scientific). Equal quantities 
of protein were prepared in nonreducing SDS-PAGE loading buffer and cathepsin 
zymography was performed as previously described [84, 85]. Briefly, samples were loaded 
into a gelatin-embedded polyacrylamide, lysate proteins were separated by molecular 
weight during electrophoresis. Following electrophoresis, cathepsins in gels were 
renatured before being incubated overnight in cathepsin-specific assay buffer at 37°C. The 
gels were then stained with Coomassie Blue, then destained. White bands indicate the 
presence of active cathepsins capable of degrading gelatin embedded in the polyacrylamide 
gel. 
7.2.4 Systems modeling of cathepsin dynamics 
 Previous studies of cathepsins in the MDA-MB-231 cell line have shown that 
cathepsin S and L are localized in distinct compartments [50]. Accordingly, we have 
assumed that cathepsin S and L do not directly interact with each other, and the network 
diagram (Figure 7-4) shows the assumed structure of both systems. The schematic shows 
relationships between the four cathepsin species, as well as the presence of the inhibitor, 
E64, which has been reported to irreversibly bind to mature active cathepsin S or L.  
 Based on the diagram shown in Figure 7-4, we have derived a system of ordinary 
differential equations (ODE) that describe cathepsin dynamics using simple mass action: 
 d[Pro]





𝑑𝑡 = kdef ⋅




𝑑𝑡 = khidef ⋅
[Mat] − kcjkr ⋅ [Mathidef] (3) 
 d[MatE64]
𝑑𝑡 = klmn ⋅
[Mat] ⋅ [E64] − kcjklmn ⋅ [MatE64] (4) 
 d[E64]
𝑑𝑡 = khi,lmn − kbtf,lmn ⋅
[E64] − klmn ⋅ [Mat] ⋅ [E64] (5) 
 
 This system of equations contains five dynamic variables corresponding to the four 
cathepsin species and E64, as well as nine kinetic parameters describing the fluxes within 
the system. Based on our zymography and Western blot data we aimed to identify values 
of the kinetic parameters that are in agreement with our experimental findings. 
Parameterization of the dynamic model was performed using a steady state approach, and 
a detailed description is provided in the Supplementary Methods. During parameter 
estimation, we investigated two different definitions for the relationship between our 
experimental measurements and the species of the ODE system. The first definition 
assumes that all cathepsin species are detectable by Western blot (WB), while only active 
mature cathepsin, [Mat], is detectable through zymography (Zymo), as defined by Eqs. 6 
and 7.      
 𝑊𝐵 = [Mat] + [Mathidef] + [MatE64] (6) 
 𝑍𝑦𝑚𝑜 = [Mat] (7) 
 
 87 
The second definition still assumes all cathepsin species are detectable by Western blot, 
but differs from definition 1 in that active mature cathepsin and E64-bound cathepsin are 
both assumed to be detectable through zymography (Eqs. 8 and 9) 
 𝑊𝐵 = [Mat] + [Mathidef] + [MatE64] (8) 
 𝑍𝑦𝑚𝑜 = [Mat] + [MatE64] (9) 
 
 Dynamic simulations were performed based on the steady state kinetic parameters 
and the system of ODEs defined by Eqs. 1 – 5. The rate of influx and outflux for E64 were 
approximated to ensure that the assumed steady state E64 concentrations were reached 
within 24 hours. Additionally, the kinetic parameters were scaled to ensure the system 
reached a steady state within 24 hrs. Numerical simulations were performed using the 
deSolve package in the R statistical language [120]. 
7.2.5 Statistical analysis 
 Zymography band intensities were quantified by densitometry in ImageJ and data 
were normalized by dividing each band intensity on a gel by the intensity measured from 
cells or tissue treated with 0 µM E64 (setting this group to 1 across all gels). Two-tailed 




7.3   Results 
7.3.1 Incubation with E64 reduces amount of active cathepsin L in MDA-MB-231 
cells, but increases the amount of active cathepsin S 
 Whether the response of increased active CatS and decreased CatL after incubation 
with the broad cathepsin inhibitor E64 was specific to MDA-MB-231 cells or could occur 
in other cell types was yet to be established. To test this, the invasive estrogen receptor 
positive MCF-7 [121], non-transformed, non-invasive breast epithelial MCF-10A [122], 
and invasive, triple negative MDA-MB-231 [123] cell lines, were incubated with 
increasing concentrations of E64 for 24 hours then lysed and prepared for cathepsin 
zymography to determine amounts of active cathepsins. E-64 incubation increased active 
cathepsin S but led to a decreased amount of active cathepsin L in MDA-MB-231 cells 
(Figure 7-1A). E64 appeared to slightly increase active cathepsin S in MCF-7 and 
MCF10A cells, but this increase was not statistically significant when averaged across 
three biological replicates. Neither MCF-7 nor MCF10A cells expressed active cathepsin 
L detectable by zymography, regardless of E64 treatment (Figure 7-1B and Figure 7-1C). 
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Figure 7-1: Incubation with E64 reduces amount of active cathepsin L in MDA-MB-231 
cells, but increases the amount of active cathepsin S. MDA-MB-231 (A), MCF-7 (B), and 
MCF-10A (C) cells were grown to confluence prior to incubation in the presence of 0, 1, 
5, 10 and 50 μM E64 for 24 hours. Cells were lysed and equal amounts of protein were 
loaded for multiplex cathepsin zymography. Densitometry was used to quantify the 
intensity of the active cathepsin S and L signals and shown in the graphs on the right for 
each cell type. There was an almost 50% increase in active cathepsin S, but a 75% loss of 
active cathepsin L in the MDA-MB-231 cells (n=3, *p<0.05, %p< 0.001). Neither MCF-7 
nor MCF-10A had detectable levels of active cathepsin L. 
 
7.3.2 E64 treatment of human normal and cancerous breast tissue yields variable 
responses of active cathepsins 
After observing increased active cathepsins following E64 treatment in one breast 
cancer cell line, the next step was to determine if this same response would occur in primary 
human tissue. Breast tissue contains multiple cell types, but we hypothesized that human 
breast tumors would exhibit similar increases in active cathepsin S following E64 



















































































pieces, and incubated in increasing concentrations of E64 for 24 hours. Normal and cancer 
tissues were homogenized in lysis buffer prior to being assayed by cathepsin zymography 
(Figure 7-2A); zymography results were quantified by densitometry (Figure 7-2B).  
 In the absence of E64, active cathepsins S and L were detectable in cancer and 
normal tissue (Figure 7-2A), consistent with previous publications indicating cathepsin 
involvement in breast cancer [124]. The amount of active cathepsin was highly variable 
between patient samples, with four of the samples showing active cathepsin V signal in 
addition to previously detected active cathepsins L and S. For the most part, E64 increased 
cathepsin S in normal tissue and decreased cathepsin L. However, in cancerous tissue, E64 
caused a significant decrease in cathepsins L, S, and V, with some amount of patient to 
patient variability. 
 
Figure 7-2 Treatment with E64 stimulates higher amounts of active cathepsin S in some 
normal, but not tumor tissue. Excised, patient-matched normal and tumor breast tissue was 
collected from seven human patients, and equally sized thin pieces were incubated in media 
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containing 0, 5, or 50 µM of E-64 for 24 hours, then lysed, and equal amounts of proteins 
were loaded for multiplex cathepsin zymography (A). Active cathepsins L and S were 
detectable in all patient samples, and active cathepsin V was detectable in four samples. 
Active cathepsins and response to inhibitor treatment was highly variable between patients, 
but active cathepsins L, S and V were significantly decreased by over 50% in the cancer, 
but not the normal tissues (n = 4-7, * p < 0.05, # p < 0.001) (B).  
7.3.3 Mass action model of cathepsin inhibition, unable to explain experimental 
results when assuming E64 inhibits zymography signal 
 A mathematical model of cathepsin L and S interactions with E64 in MDA-MB-
231 cells was constructed to explain the counterintuitive responses to E64. Reactions in the 
model include: synthesis/production of procathepsins, activation from procathepsin to the 
mature, active cathepsin, degradation, inactivation, and inhibition by E64 (Figure 7-4). 
Based on this diagram, we designed a system of ordinary differential equations (ODE) 
using simple mass action functions (Eqs. 1 – 5) that describe cathepsin dynamics. This 
system of equations contains five dynamic variables corresponding to the four cathepsin 
species and E64, as well as nine kinetic parameters describing the fluxes within the system. 
Based on our zymography and Western blot data we aimed to identify values of the kinetic 
parameters that are in agreement with our experimental findings. 
The model was fit to Western blot and cathepsin zymography data collected from 
MDA-MB-231 cells treated with 0, 10, or 50 µM E64 for 24 hours under the assumption 
that zymography detected mature, but not inactive, cathepsins (Mat), since enzymes must 
be active to generate a signal. The procathepsins, mature cathepsin, inactivated and 
inhibited cathepsin forms would all be detected by Western blots. Assumptions of the 
model also were that cathepsin L was in the cytoplasm and cathepsin S was intravesicular 
as shown previously [50].  Parameterization of the dynamic model was performed using a 
steady state approach. We assumed that the E64 concentration in the lysosomal 
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compartment, which is where cathepsin S is localized, reaches a steady state concentration 
equal to the specified media concentration after 24 hours. This assumption was made 
because time course measurements using 50 µM E64 in MDA-MB-231 cells found the 
amounts of zymography detectable cathepsins L and S had largely plateaued by 24 hours . 
Steady state concentrations in the cytosol, which is where cathepsin L is localized, were 
scaled based on an approximation that the cytosol volume is 35 times larger than the 
lysosomal volume. Based on these assumptions, and the proposed system of ODEs (Eqs. 1 
– 5), steady state equations were defined for the three tested concentrations of E64: 0 µM, 
10 µM, and 50 µM. This system of equations includes seven unknown steady state kinetic 
parameters, as well as steady state concentrations of cathepsin species that are not directly 
measurable based on available experimental data. Detailed equations (Equ 6 – 28) and 
parameter estimation steps are included in Appendix 1. 
The steady state equations were reduced to a system of six equations (Eqs. 29 – 34) 
with six cathepsin-related kinetic parameters as unknowns. Eqs. 29 – 32 define the 
relationship between the kinetic parameters and the steady state concentrations, while Eqs. 
33 and 34 serve as constraints connecting the steady state concentrations to the 
experimental data.  
 [Mat]z{|: − [Pro]{|: ⋅
𝑘;H&
𝑘}B;H& + 𝑘!~ + 𝑘mn ⋅ [E64]z{|:
= 0 (29) 
 [Mat]{|: − [Pro]{|: ⋅
𝑘;H&
𝑘}B;H& + 𝑘!~ + 𝑘mn ⋅ [E64]{|:
= 0 (30) 
 kdef ⋅ [Pro]{|: − [Mat]{|: ⋅ khidef + kcjk = 0 (31) 
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 khidef ⋅ [Mat]{|: − kcjkr ⋅ [Mathidef]{|: = 0 (32) 
 [Mat]z{|: + [Mathidef]z{|: + [MatE64]z{|: −𝑊𝐵z{|: = 0 (33) 
 [Mat]{|: + [Mathidef]{|: + [MatE64]{|: −𝑊𝐵{|: = 0 (34) 
 
Parameter estimation was initially performed for cathepsin S and L, where the 
squared residuals for Eqs. 29 – 34 were minimized with respect to the six kinetic 
parameters. These equations define a nonlinear root finding problem composed of six 
equations and six unknowns, where an exact solution cannot be determined analytically. 
Therefore, a numerical approximate solution was obtained using a newly developed 
optimization algorithm for black-box problems by identifying kinetic parameter values that 
minimized the sum of the squared residuals for Eqs. 29 – 34 [125]. The applied algorithm 
is surrogate-based, and utilizes a special class of polynomials to approximate the 
relationship between the optimization variables and the objective function. For this 
problem the optimization variables were the parameter values and the sum of the squared-
residuals of the steady-state equations was the objective function that was being minimized. 
The algorithm starts with an initial set of samples that fall on a Smolyak sparse-grid, and 
then iteratively samples the parameter space by using the polynomial approximation to 
predict were the best samples lie and then updates the approximation following the 
collection of new samples. Local optimization of the polynomial approximation is also 
used in identifying which samples to collect next (i.e. the parameter combinations to 
evaluate), and criteria based on the improvement of the polynomial approximation are used 
for determining convergence. Based on this model, parameter estimation for cathepsin L 
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proved successful with the identification of a solution with low residuals, but for the case 
of cathepsin S no reasonable solution was found (Table 7-1). 
 
Table 7-1: Residuals for initial model, assuming E64 bound cathepsin S is undetectable by 
zymography 
 
Residuals Squared (μM2) 
Equation Cathepsin L Cathepsin S 
29 3.5E-09 7.836 
30 1.6E-06 8.302 
31 6.2E-08 1.014 
32 1.5E-08 3.0E-04 
33 1.3E-09 8.978 







Figure 7-3: Initial model accurately fits cathepsin L but not cathepsin S zymography data. 
Cathepsin L (A) and cathepsin S (B) model fits to experimental Western blot (WB) and 
zymography (Zymo) data at different dosages of E64. The cathepsin L model fits the 
zymography and Western blot data. The cathepsin S model is able to fit the Western blot 
data, but does not predict the increase in zymography signal following E64 treatment seen 
in MDA-MB-231 cells. 
 
 The model was able to simulate the behavior of E64 reducing active cathepsin L, 
but not the unexpected result of E64 treatment increasing active cathepsin S (Figure 
7-3A&B).  A number of alternative reaction scenarios were considered including E64 
affecting rates of activation and degradation of cathepsins S and L. These repreliminarily 
modeled to determine if they could fit the data and better describe the system in action, but 
none of these models were able to recapitulate the results of increased active cathepsin S 
as seen in the zymography results. Transcriptional regulation of cathepsin S was not 
considered because E64 treatment did not affect cathepsin S mRNA or protein in MDA-
MB-231 cells [50]. After exhausting these alternative explanations, it was necessary to 
reassess our initial assumption that cathepsins are only detectable by zymography when 
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Figure 7-4: Cathepsins L and S are located in different intracellular compartments, leading 
to different responses to inhibitors with different entry mechanisms. Cathepsins L and S 
are translated in the rough endoplasmic reticulum, trafficked through the Golgi apparatus 
to endolysosomal vesicles bound for lysosomes (A). Cathepsin S remains in endolysosomal 
vesicles, while cathepsin L enters the cytoplasm (B). E64 cannot freely pass through the 
plasma membrane, and enters the endolysosomal vesicles, where it can bind cathepsin S, 
before leaking into the cytoplasm where cathepsin L is available to bind (C). E64d is a 
derivative of E64 that contains an ethyl ester which allows it to cross the cell membrane. 
Once in the cytosol, the ester is hydrolyzed by cytoplasmic esterases, trapping it in the 
cytoplasm where it can bind to cathepsin L (D). Lysosomotropic inhibitors, modeled on 
lipid hormones capable of freely moving across the plasma and lysosomal membranes 
where they can bind cathepsins L and S respectively (E). Schematic representation of 
cathepsin E64 model architecture. Cathepsins are translated in pro form, activated to 
mature form, then inactivated, degraded, or bound by E64. 
7.3.4 E64 does not block cathepsin S zymography signal under cell lysate conditions 
E64 is considered an irreversible cathepsin inhibitor, due to the formation of a 
covalent bond between the C2 atom of the E-64 epoxy ring and the active site cysteine of 
the cathepsin, as well as hydrogen bonding between E-64 and polar residues near the 
cathepsin active site [93]. However, under the partial denaturing conditions of zymography 
followed by refolding after the electrophoresis, the cathepsin-E64 complex could 
potentially be disassociated or shifted into a non-inhibitory conformation. To test the 
hypothesis that cathepsin S and E64 were uncoupling during the denaturation/renaturation 
of zymography, MDA-MB-231 cells were cultured as before, with 0 or 50 µM E64 for 24 














Mat = Active mature cathepsin
Matinact = Inactive mature cathepsin
MatE64 = Cathepsin bound to E64
E64 = Cathepsin inhibitor E64
Parameters:
kprod = Rate of cathepsin production 
kact = Rate of cathepsin activation
kinact = Rate of cathepsin inactivation
kE64 = Rate of cathepsin inhibition by E64
kdeg = Rate of degradation for active mature cathepsin
kdegI = Rate of degradation for inactive mature cathepsin
kdegE64 = Rate of degradation for inactive mature 
cathepsin:E64 complex
kin,E64 = Rate of E64 influx
kout,E64 = Rate of E64 outflux
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added to the cell lysate, assuming additional E64 would bind to free cathepsin L and S in 
the lysate. MDA-MB-231 cells treated with 50 µM E64 showed decreased active cathepsin 
L and increased active cathepsin S, consistent with previous results (Figure 7-5A). There 
was no change in the zymography signal for those samples that had an additional 10 µM 
E64 added to the lysate in lysis buffer compared to the control samples for neither cathepsin 
L nor S (Figure 7-5A).  
To ensure that 10 µM E64 was sufficient to bind and inhibit cathepsins, a zymogram 
was run in parallel, but was treated differently after electrophoresis and cathepsins were 
renatured; the gel was incubated in cathepsin assay buffer containing 10 µM E64. 
Incubation in assay buffer with 10 µM E64 completely abrogated the cathepsins’ 
zymography signal, even in the RAW264.7 macrophage lysate used as a positive control 
(Figure 7-5B). Densitometry of the active cathepsin zymography signal is shown (Figure 
7-5C). The ability of E64 to inhibit cathepsins when added to the assay buffer, but not when 
added to lysate, suggests the zymography process disrupts the inhibitory properties of E64, 
possibly through conformational changes to the cathepsin active site brought on by sodium 
dodecyl sulfate (SDS), detergents in the lysis buffer, basic pH of lysis buffer or 
electrophoresis buffers. This potential unbinding of E64 under non-reducing SDS-PAGE 
conditions was not expected because E64 has been classified as an irreversible covalently 
binding inhibitor of the active site cysteine [93], but this led to reconsideration of the 
experimental data to which the computational model was being fit.  
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Figure 7-5: E64 does not block cathepsin S zymography signal under cell lysate conditions. 
MDA-MB-231 cells were cultured with 0 or 50 μM E64 for 24 hours then the cells were 
lysed and lysate collected from each of the incubation conditions. Aliquots of each lysate 
were then incubated with 0 or 10 μM E64 for 10 minutes to allow binding of E64 to active 
cathepsins. Then equal protein amounts from these samples were prepared for cathepsin 
zymography as usual (A), or 10 µM fresh E64 was added to the overnight incubation step 
during cathepsin degradation of the embedded gelatin (B). There was no observed 
difference in active cathepsin zymography signal between lysates treated with additional, 
fresh E64 or not, but incubation with E64 during the degradation completely blocked all 
active cathepsin zymograms signal. Densitometry was used to quantify the zymography 
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7.3.5 Correcting for cathepsin S-E64 zymography signal significantly improves 
model fit, parsing inhibited cathepsin from uninhibited cathepsins, and active 
from inactive conformations 
The mathematical model was revised to incorporate the ability of cathepsin S bound 
by E64 in living cells to generate a zymography signal, as shown schematically in Figure 
7-6A. Model fitting with these new assumptions generated parameters with much lower 
residuals for the cathepsin S parameters (Table 2), recapitulating the experimental results 
garnered from Western blots and zymography (Figure 7-6C&D). Steady state simulations 
of the model predicted dose dependent accumulation of cathepsin-E64 complexes for both 
cathepsins L and S (checkerboard segments of graphs), but only cathepsin S-E64 
complexes, not cathepsin L-E64 complexes, were allowed to contribute to zymography 
signal (Figure 7-6B). Taken together, the red signals indicate zymography signal 
generating species with a direct relationship with E64 concentration for cathepsin S but an 












Table 7-2: Residuals for revised model, assuming E64 bound cathepsin S is detectable by 
zymography 
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 Model parameters governing cathepsin production (kprod), activation (kact), 
inactivation (kinact), and degradation (kdeg) were estimated to be several orders of magnitude 
greater for cathepsin L than cathepsin S (Table 7-3), indicating cathepsin L production and 







Table 7-3: Parameters for final MDA-MB-231E64 model 
 
Parameter Cathepsin L Cathepsin S 
kProd 4.67E-02 1.40E-05 
kAct 9.34E-04 2.75E-07 
kInact 3.91E-04 5.71E-08 
kDeg 1.31E-03 3.76E-07 
kDegI 4.77E-04 1.34E-07 
kE64 1.81E-03 7.05E-09 
kDegE64 9.24E-04 1.81E-07 
 
 
Figure 7-6: Correcting for cathepsin S-E64 zymography signal significantly improves 
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Revised model architecture assumes cathepsin S is detectable by Western blot when in its 
pro state, free mature state, inactive state or when bound by E64 and detectable by 
zymography when in its free mature state or when bound by E64 (A). Model predictions 
for enzyme species at steady state for cathepsins S and L. The model predicts that E64 
treatment increases cathepsin bound E64 complexes and decreases free cathepsins in a dose 
dependent manner. E64 is also predicted to decrease non-E64 inactivated cathepsin L by 
over 50% while non-E64 inactivated cathepsin S is less affected (B). The model is able to 
recapitulate experimental results for cathepsin L (C) and cathepsin S (D). 
 
 
7.3.6 A priori predictions of dynamic responses of cathepsins L and S to different 
classes of cathepsin inhibitors 
Following the successful construction of the steady state cathepsin L and S model, 
we were interested in constructing a dynamic model with utility to describe the kinetics of 
different classes of cathepsin inhibitors binding to and inhibiting cathepsins over time. The 
model includes extracellular, lysosomal (cathepsin S) and cytoplasmic (cathepsin L) 
compartments, and the class of cathepsin inhibitor determined their ability to move 
between these compartments: membrane impermeable cathepsin inhibitor such as E64, 
membrane permeable inhibitor such as E64d, and a lysosomotropic inhibitor, which made 
up a number of early cathepsin inhibitors that advanced to clinical trials but were 
unsuccessful [119, 126, 127] (Figure 7-7A). The steady state cathepsin E64 models were 
used to parameterize time course models to predict cathepsin dynamics following inhibitor 
treatment. Inhibitor treatment was modeled as a bolus of 10 µM at time point 24 hours, and 
models were simulated until 48 hours.  
Membrane impermeable E64 was modeled as an endocytosed inhibitor taken up by 
the cell into endolysosomal compartments that fuse with lysosomes, then able to bind to 
cathepsin S. The model assumes the small molecule E64 is able to leak out of the 
endolysosomal compartment into the cytosol in a similar manner to other lysosomal 
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contents that have been shown to move into the cytoplasm in cancer cells [128]. Once these 
minute amounts of E64 are in the cytoplasm, they are able to bind to cathepsin L present 
in the cytoplasm, as demonstrated by immunocytochemistry previously [50]. The dynamic 
model predicted that cells treated with E64 would accumulate cathepsin L-E64 and 
cathepsin S-E64 complexes, peaking 24 hours after treatment, resulting in elevated 
cathepsin S zymography signals and diminished cathepsin L zymography (Figure 7-7B), 
as was observed experimentally (Figure 7-1). Cathepsin L was predicted to reach peak 
inhibition in under 1 hour, compared to cathepsin S, which did not reach its maximum 
zymography signal until 12 hours after inhibitor treatment. 
For E64d, the membrane permeable inhibitor due to addition of an ethyl ester that 
is removed by cytosolic esterases, effectively trapping E64d in the cytoplasm, the results 
were different. The model predicted E64d would have little effect on cathepsin S, since it 
was located in the endolysosomal compartment. However, E64d would be extremely 
effective at inhibiting cathepsin L due to its ease of crossing the membrane and entering 
the cytoplasm. According to the simulation, E64d was more effective than E64 at inhibiting 
cathepsin L (22% inhibition for E64 and nearly 100% inhibition for E64d), but the 
inhibition subsided more quickly since the greater influx of inhibitor resulted in a more 
rapid depletion of free inhibitor (Figure 7-7C), compared to the limited release of E64 into 
the cytoplasm that resulted in a much slower return to baseline for free cathepsin L. As 
predicted, cathepsin S responded less to E64d than E64 (22% increase in zymography 
signal for E64 compared to 7% increase for E64d). The predicted greater inhibitory 
capacity of E64d compared to E64 on cathepsin L and lack of response in cathepsin S are 
consistent with experiments using E64d in MDA-MB-231 cancer cells, which found 1µM 
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E64d inhibited intracellular cathepsin L at a 1µM dose, while having no effect on cathepsin 
S at any dosage [50]. 
The third class of lysosomotropic inhibitors were modeled as moving freely across 
lipid membranes and through compartments, from extracellular to cytosolic to 
endolysosomal. Lysosomotropic inhibitors showed rapid binding to cathepsins S and L to 
form complexes. The magnitude of inhibition of cathepsin L by the lysosomotropic 
inhibitor (85%) was greater than for E64, the membrane impermeable inhibitor (22%). The 
lysosomotropic inhibitor provoked the largest increase in cathepsin S zymography signal 
(43% for lysosomotropic vs. 22% for E64). These simulations are consistent with studies 
of lysosomotropic inhibitors that have shown high efficacy in binding target and off-target 
cathepsins and side effects caused by these potent inhibitors [117, 118, 126]. 
 
Figure 7-7: Dynamic model predicts different classes of cathepsin inhibitors provoke 
divergent responses by cathepsins L and S. Schematic representation of dynamic models 






























































































cytoplasmic compartments, respectively. Inhibitors can enter the endolysosomal 
compartment through endocytosis, or enter the cytoplasmic compartment through passive 
diffusion. Inhibitor can also pass from endolysosomal to cytoplasmic through lysosomal 
leakage  (A). Dynamic model predictions of cathepsin L and S states, and predicted 
zymography and Western blot results following treatment with E64 (B) E64d (C) or a 
lysosomotropic inhibitor (D). Steady state model parameters were scaled to create a 
dynamic model of cathepsin inhibition over time. A treatment of 50 μM inhibitor was 
added at 24 hours, and cathepsin dynamics were predicted for several days following 
treatment to allow the system to move toward its steady state. E64 was able to bind to both 
cathepsins L and S through endocytosis and subsequent leakage out of the endolysosomal 
compartment and into the cytoplasm. Due to its confinement in the cytoplasm, E64d was 
much more effective in binding cathepsin L than cathepsin S, which is consistent with 
previous experimental data showing low dosages of E64d can inhibit cathepsin L while not 
affecting cathepsin S. E64d also inhibited cathepsin L much more rapidly than E64, since 
it could cross the cell membrane and enter the cytoplasm directly. Lysosomotropic inhibitor 
bound both cathepsins L and S more rapidly than E64, resulting in loss of free cathepsins 
L and S. 
 
7.4   Discussion 
This work shows treatment with a cathepsin inhibitor can increase different active 
cathepsins in multiple cell types and primary tissue, suggesting there is a common 
mechanism among these cell types that should be considered when designing inhibitor 
treatment regimens. Ex vivo tumor biopsy specimens from different patients displayed 
significant person-to-person heterogeneity in endogenous active cathepsins and in response 
to inhibitor treatment. The presence of stromal cells, such as tumor associated 
macrophages, could explain some of the variability observed in the primary tumor samples 
as macrophages are known to have donor-specific variation in active cathepsin expression 
[83]. Successful clinical treatment of cancer metastasis with cathepsin inhibitors will 
require better understanding of the proteolytic interactions, in order to effectively suppress 
target proteases contributing to metastasis, while avoiding impacting proteases that would 
provoke unexpected side effects. Additionally, these results underscore the importance of 
assaying active cathepsins, in addition to total cathepsins, during inhibitor clinical trials. 
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The models we developed were able to differentiate between inhibitor-bound, active, and 
inactive cathepsin species, which are difficult to measure experimentally and can confound 
in vivo and in vitro experiments. Finally, the dynamic models of different classes of 
cathepsin inhibitors that have been deployed in clinical trials, demonstrate how inhibitor 
trafficking and access to subcellular compartments can have drastically divergent effects 
on active cathepsins located in different intracellular compartments. 
Cathepsins are attractive targets for multiple diseases including cancer, 
osteoporosis and atherosclerosis, but off-target effects and unexpected responses to 
cathepsin inhibitor treatments have prevented their clinical adoption. This work sought to 
explain a previously documented non-intuitive response to cathepsin inhibitor treatment in 
breast cancer cells, a simultaneous increase in active cathepsin S and decrease in cathepsin 
L following E64 treatment. Several different cells related to breast cancer tumors were 
experimentally tested to determine the distribution of the non-intuitive E64 treatment 
response, including different transformed and non-transformed breast cancer cell lines, 
primary tumor and patient matched normal tissue samples, and a human macrophage cell 
line.  
This work focused on the small molecule inhibitor E64 as a model cysteine 
cathepsin inhibitor with cross-reactivity. To test the effects of E64 on primary tissue, 
patient matched normal and tumor samples were incubated with E64. The patient samples 
displayed diverse endogenous cathepsin signatures, including cathepsins L, S and V. This 
high degree of proteolytic variability agrees with our previous findings of a high degree of 
person-to-person variability in endogenous active cathepsin and cystatin expression among 
monocyte derived macrophages isolated from healthy donors [83]. On average, E64 
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treatment decreased active cathepsins in tumor samples. However, several normal tissue 
samples had increased active cathepsins following E64 treatment. These results highlight 
the difficulty in designing effective cathepsin inhibitor regimens due to high patient 
variability in endogenous proteases.  Additional experimentation will be required to 
determine the roles of different cells in complex in vivo systems, including tumor tissue, 
which is composed of many different cells including cancer-associated fibroblasts, tumor 
associated macrophages, other leukocytes, endothelial cells and adipose cells, many of 
which are known producers of cysteine cathepsins [25]. Additionally, breast cancer cells 
are known to be highly heterogeneous even within the same primary tumor [129], further 
underscoring the need for in silico tools to study variation in proteolytic inhibitor 
responses.  
To explore the effects of E64 on other cancer associated cells, macrophages were 
treated with E64 and active cathepsins were quantified. Tumor associated macrophages are 
abundant in breast tumors, comprising up to 50% of the tumor mass [10]. Cysteine 
cathepsins produced by tumor associated macrophages have been shown to promote tumor 
growth and metastasis, angiogenesis, and even to suppress chemotherapy [7, 130]. E64 
treatment significantly increased active cathepsin S and active cathepsin V in the Thp-1 
human macrophage cell line. Increased active cathepsins in Thp-1 macrophages suggests 
this effect is conserved across cells of multiple lineages, including epithelial cells derived 
from the endoderm and macrophages derived from the mesoderm. Additionally, the 
increase in active cathepsin V indicates this response is not limited to cathepsin S, but could 
also affect other proteases, particularly other cysteine cathepsins due to the high degree of 
protein identity shared between family members. 
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The failure of our original model assumption, that cathepsins bound by E64 are 
undetectable by cathepsin zymography, to explain the observed increase in active cathepsin 
S following E64 treatment led us to question this assumption and test it experimentally. 
Treated lysate with additional E64 did not affect the resulting zymography signal, 
suggesting E64 loses its inhibitory capacity during non-reducing electrophoresis. We 
suspect E64 is playing a stabilizing role on cathepsin S during E64 incubation, where free 
cathepsin S becomes bound to E64 instead of naturally inactivating due to changes in 
intracellular compartment pH or oxidative conditions. Once E64 binding is interrupted 
during electrophoresis, the cathepsin S bound by E64 may regain its ability to degrade 
substrate to generate the elevated zymography signal observed. E64 does not provide the 
same stabilizing effect intracellularly as it provided to cathepsin S, resulting in loss of 
active cathepsin L signal, following cellular treatment with E64. This could be caused by 
differences in the intracellular environments of the two enzymes in MDA-MB-231 cells, 
since cathepsin L is dominantly in the cytoplasm in these cells while cathepsin S was 
confined to the endolysosomal compartment. Cathepsin S is also known to tolerate neutral 
pH more effectively than cathepsin L, which could be quickly denatured in the more neutral 
pH of cytoplasm or basic pH of lysis buffer, regardless of E64 binding [131]. 
Dynamic simulations of different classes of cathepsin inhibitors showed the 
importance of intracellular trafficking mechanisms on the specificity and strength of 
inhibition. Lysosomotropic inhibitors elicited large responses from both cathepsins L and 
S due to high cellular uptake and accumulation in the lysosomes, consistent with previous 
results showing high intracellular potency, but poor selectivity among lysosomotropic 
cathepsin inhibitors [118, 119, 127].  
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Previous studies of cathepsin inhibition in rodent models have shown the ability of 
cathepsin inhibitors to affect the expression and activity of cysteine cathepsins. Cathepsin 
B, H and L had increased half lives in the livers of rats treated with the potent cysteine 
cathepsin inhibitor EP-475 (E-64c) [132]. While cathepsin L or cathepsin S protein were 
not increased following E64 treatment, it is possible that the protein could accumulate over 
a period of time longer than 24 hours. Treatment with the weaker binding, reversible 
inhibitor leupeptin elicited increased cathepsin B and other lysosomal hydrolase activity in 
rat fibroblasts and mouse bone tissue, measured with reporter substrates [133]. However, 
enzyme activity was abolished when the rat fibroblasts were treated with E64.  
This work suggests inhibitors can protect specific enzymes resulting in long-term 
increases in activity following the unbinding of an inhibitor. Small molecule inhibitor 
interactions or interference with cystatins, the endogenous protein inhibitors of cathepsins, 
must also be included. Previous work in our lab has shown cystatin C can elicit the same 
preservation of active cathepsin S, while interestingly failing to inhibit cathepsin L [50]. 
Cathepsin stability is greatly affected by binding substrates and effector molecules such as 
glycosaminoglycans, the presence of which can increase cathepsin K half-life at neutral pH 
from 7 to 190 minutes [65]. Similarly, binding to E64 could preserve cathepsin S activity, 
creating a reservoir of active cathepsins capable of degrading substrate following inhibitor 
unbinding. Our model results suggest even broad-spectrum inhibitors can have 
diametrically opposed enzyme-specific impacts, preserving or inhibiting activity 
depending on properties of the enzyme and its intracellular location. The exact effector 
molecules and mechanisms responsible for this differential response to cathepsin inhibitor 






8 CONCLUSIONS AND FUTURE DIRECTIONS  
8.1 Major Findings 
 In this dissertation, we took important steps forward in developing experimental 
and computational tools to predict proteolytic dynamics in multiple cell types involved in 
breast cancer metastasis. We also identified and explored unexpected responses to 
perturbations of those networks, including cathepsin inhibitor treatment and cathepsin 
cannibalism.  
 We were able to determine the limits of detection of cathepsin zymography for 
measuring active cathepsins, particularly cathepsin V, in human monocytes. Validating this 
tool will provide valuable insight when applying cathepsin zymography to complex 
multicellular tissue samples, such as breast tumors, in the future, potentially predicting the 
macrophage content of primary tumors based on active cathepsin V content. Additionally, 
we characterized the intracellular and extracellular accumulation rates of cathepsins L and 
S in human macrophages. These data reveal significant cathepsin-specific differences in 
protein turnover and accumulation and will inform the development of future 
computational models of proteolytic dynamics in macrophages. We found that cellular 
cathepsin L is almost completed depleted following 24 hours of translation inhibition, 
suggesting a short intracellular half-life due to high cathepsin L turnover or secretion. 
Interestingly, while cathepsin L was secreted rapidly, it reached a steady state 
concentration by 8 hours. Cathepsin L reaching a steady state suggests either the enzyme 
is being degraded extracellularly or that macrophages adjust rates of cathepsin L 
production or secretion over time, possibly in response to concentrations of intra or 
extracellular cathepsin L. In contrast, intracellular cathepsin S levels remained relatively 
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constant following translation inhibition, and extracellular levels increased linearly over 
the 24-hour time course, though more slowly than the initial secretion of cathepsin L. This 
points to a lack of extracellular degradation of cathepsin S, or a difference in control over 
translation and secretion regulation between the two enzymes, since extracellular cathepsin 
S levels did not reach a steady state after 24 hours. 
 We also documented an unexpected increase in active cathepsins V and S, and 
decrease in active L following cathepsin inhibitor treatment in macrophages. We went on 
to explore a similar phenomenon in breast cancer cells, but differences in the response 
suggest there may be significant cell type specific effects relevant to cathepsin inhibitor 
treatment. The macrophages had increased active cathepsin V, which was not detectable in 
the breast cancer cells, showing this phenomenon is not unique to cathepsin S. The 
macrophages also had increased pro and mature cathepsin S and pro cathepsin L, while no 
changes in pro or mature cathepsins L or S were detectable in the breast cancer cells. One 
hypothesized reason for this difference in response is an increased uptake of cathepsin 
inhibitor in highly phagocytic macrophages as compared to cancer cells, leading to a large 
response in pro and mature protein levels resulting in detection in macrophages, but not in 
cancer cells. Additional experimental and computational investigation will be required to 
uncover other factors potentially causing this upregulation in response to inhibitor 
treatment and reasons for its differential behavior based on cell type. 
 Cathepsin cannibalism had previously been documented in vitro, and we observed 
it in an engineered cellular system mimicking the dynamics between macrophages and in 
breast cancer cells. We developed and parameterized a mathematical model of cathepsin 
dynamics to parse the relative contributions of cathepsins K and S to overall cathepsin K 
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degradation. We identified four distinct families of solutions, which predicted different 
relative contributions of cathepsins S and K to cathepsin K degradation. We identified 
cathepsin K activation rate as a critical parameter separating the families into groups where 
cathepsins were not involved in degradation vs. groups where cathepsins played a 
significant role in cathepsin K degradation. Repeating the parameter estimation after 
establishing new bounds on cathepsin K activation rate yielded three new solution families: 
CatK Dominant, Equal Partners and CatS Featured. While these solutions appeared to fit 
the data similarly, extrapolation revealed the CatS Featured solutions had the most 
consistent and least oscillatory behavior, providing evidence for their validity as biological 
solutions. All of the refined solutions agree that cathepsin K plays at least as large a part in 
its own degradation as cathepsin S, a surprising result, given the in vitro data of the original 
cathepsin cannibalism studies which found cathepsin S to be more important to cathepsin 
K degradation. However, cathepsin K having a large impact on its own degradation is 
consistent with the most recent in vitro modeling, which suggests cathepsin K 
autodigestion could be several times faster than cathepsin S on cathepsin K degradation, at 
pH 6. 
 Cathepsin mRNA for protein overexpression was developed and validated in 
HEK293T and breast cancer cells. Most of the mRNA was able to rapidly induce a large 
amount of protein overexpression. However, only cathepsin V was found to be catalytically 
active by zymography. Overexpressed cystatin C was found to reduce DQ elastin 
degradation in conditioned media of transfected cells, suggesting it has inhibitory potential 
and can be used in experimental models of cathepsin inhibition. We also tested the 
hypothesis that overexpression of different cathepsins could induce a change in the 
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expression of other cathepsin family members. While we saw no change in off-target 
cathepsins following transfection, it is possible that this result would be different if the 
mRNA were overexpressing catalytically active enzymes. 
 Pro and mature cathepsins L and S were successfully purified from the conditioned 
media of HEK293T cells stably transfected to overexpress cathepsins L or S. 
Unfortunately, these enzymes were not catalytically active following purification. 
Experiments with RAW macrophages optimized an activation protocol able to activate 
macrophage media cathepsins. However, this protocol was unable to activate purified 
procathepsins or even unpurified cathepsins from the media of overexpressing HEK cells. 
Additional experiments will be required to optimize an activation protocol for cathepsins 
in the conditioned media of HEK cells. 
 Previous work had shown E64 treatment could increase active cathepsins in cancer 
cells. We extended this work by treating multiple cancer cell lines and primary patient 
tissue with E64 and measuring active cathepsins. Active cathepsin S was slightly increased 
in other cancer cell lines and non-cancerous tissue, but significantly decreased in primary 
tumors. Additionally, primary patient tissue displayed considerable heterogeneity, both in 
endogenous active cathepsins and response to inhibitor treatment. We developed a 
computational model of intracellular cathepsin production, inhibition, inactivation and 
degradation that motivated an experiment to test the ability of zymography to detect E64 
bound cathepsins. Experimental results confirmed E64 bound cathepsins can be detected 
by zymography. This surprising result changed our understanding of the inhibitor response 
we had previously seen, since the increase in active cathepsin S could now be explained by 
E64 preserving the activity of cathepsin S similar to how the weak binding cathepsin 
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inhibitor leupeptin is used in zymography lysis buffer to preserve cathepsin activity [85]. 
Cathepsin L does not seem to be preserved by E64 binding intracellularly, possibly due to 
its location in the cytoplasm of MDA-MB-231 cells. We also parameterized a dynamic 
model capable of simulating cathepsin inhibitors with different intracellular trafficking 
mechanisms, demonstrating how different cathepsin inhibitor responses can be based on 
the location of the target cathepsin and trafficking method of the inhibitor. 
8.2 Future Research Directions 
8.2.1 Proteolytic profiles of human macrophages 
 The biggest question I have about the human macrophage data is what is causing 
extracellular cathepsin L levels to grow quite quickly for the first 4-8 hours after CHX 
removal, then plateau to a steady state for the rest of the time course. Extracellular 
degradation of cathepsin L by some protease seems likely. Cathepsin S is one possible 
candidate due to its stability at neutral pH. However, our in vitro results have not shown it 
to be a particularly aggressive degrader of cathepsin L. Another possible candidate is the 
aspartyl protease cathepsin D, which has been show to degrade inactive cathepsin L in vitro 
[134]. Cathepsin D is more active in the acidic environment of the lysosome, but a low pH 
pericellular environment could allow it to cleave secreted cathepsin L [109]. Characterizing 
the secretion rates of macrophages isolated from different primary donors could also be 
valuable to the development of personalized models to predict responses to cathepsin 
inhibition among different individuals. 
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8.2.2 Cathepsin dynamics in multicellular systems 
 While documenting cathepsin cannibalism in an engineered cellular system was a 
significant step from in vitro studies, it falls short of showing cathepsin cannibalism in a 
more physiologic system. The obvious next question is where does cathepsin cannibalism 
occur naturally?  
 A likely physiologic site of cathepsin cannibalism is the lysosome. The low pH and 
reducing environment of the lysosomes promote activity of many cathepsins, and a variety 
of cathepsins and other lysosomal hydrolases are found here. Interestingly, lysosomes 
exhibit a significant amount of variation in morphology and luminal contents, even among 
the lysosomes in a single cell [135]. This could complicate efforts to identify effects of 
lysosomal cathepsin cannibalism and other proteolytic network dynamics in lysosomes, 
since different versions of these interactions could be playing out differently across the 
lysosomes of a single cell. Another potential site of cathepsin cannibalism is the cytoplasm 
during apoptosis.  
 I believe cathepsin and cystatin C mRNA will prove to be invaluable tools for 
studying cathepsin proteolytic networks in vivo once the details preventing forming active 
protein are ironed out. Since the transfection efficiency of the mRNA is so high, even 
among primary cells, we could induce overexpression of cathepsin S in human osteoclasts, 
potentially degrading cathepsin K, slowing collagen degradation and bone resorption. The 
creation of a host of cannibalism resistant cathepsin mutant mRNAs could provide 
experimental evidence in cellular or even animal models of cathepsin cannibalism as a 
regulatory mechanism. 
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8.2.3 Molecular approaches to probing the proteolytic network 
 Cathepsin and cystatin C mRNA is an exciting new tool to perturb proteolytic 
networks and discover unknown regulatory functions of cathepsins in multiple cell types. 
Unfortunately, while most of the mRNA produces considerable amounts of protein, the 
only protein that seems to be catalytically active is cathepsin V. Determining why these 
mRNA overexpressed proteins are inactive could be a significant undertaking, but the 
ability to transiently overexpress wildtype and mutant cathepsins with high efficiency in a 
wide variety of cell types and even in animal models should be well worth the effort. I 
believe there are two main possibilities for why these overexpressed proteins are inactive, 
improper folding or incorrect intracellular trafficking. A relatively simple experiment to 
check if the protein is properly folded is to attempt to activate the overexpressed proteins 
through the use of a low pH buffer and dextran sulfate, similar to the one used in Chapter 
6. However, a more direct method for measuring whether these proteins are folded is 
circular dichroism and comparing to recombinant protein samples, which are known to be 
catalytically active. If either of these results confirm the protein is folded, the culprit is 
likely improper trafficking from the Golgi to endosomes and lysosomes. Potential areas to 
focus on in this pathway are glycosylation, mannose 6-phosphate tagging and mannose 6-
phosphate receptor mediated sorting. 
 If these issues can be resolved and the mRNA can induce the production of active 
cathepsins in multiple cell types, a huge variety of experimental possibilities open up. 
While we were able to attempt to test our hypotheses related to the overexpression of one 
species of cathepsin affecting the expression or activity of another, the lack of catalytic 
activity in our overexpressed cathepsins could have prevented the overexpressed enzymes 
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from impacting the cells, disguising any regulatory effects. Repeating these experiments 
with catalytically active overexpressed cathepsins could reveal hypothesized regulatory 
links between different cathepsin family members in cells. Primary cells, especially those 
that do not divide normally like macrophages, can be difficult to transfect with DNA, but 
mRNA transfection is much more successful in these cell types [111]. Cathepsin mRNA 
could be used to better model tumorigenic macrophages by inducing overexpression of 
different cathepsins in a tumor model. Cathepsin overexpression could also be used to 
directly compare the relative impacts of different cathepsins on a variety of experimental 
variables such as tumor invasion, response to cathepsin inhibitors, vascular remodeling, 
degradation of fibrin clots, and any other experimental model investigating the role of 
cysteine cathepsins. 
 Protein overexpression with mRNA has also been shown to work in animal models. 
In cathepsin knockout mice, another related protease often shoulders some of the work 
normally done by the knocked out cathepsin. Transfecting knockout mice to overexpress 
the previously knocked out cathepsin is a potential application to study the relative 
contributions of different proteases to similar functions in vivo. Additionally, the cystatin 
C mRNA we have seems to successfully inhibit cathepsins, so it could potentially be used 
to perturb cathepsin systems in cells or animal models. Cystatin C levels can vary 
considerably between individuals, so cathepsin mRNA would allow us to better recreate 
those person-to-person differences in vivo. 
8.2.4 Cathepsin purification and activation 
 By successfully purifying cathepsins S and L from cell media, I was able to help 
take the lab one step closer to producing our own mutant and wildtype recombinant 
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cathepsins on demand. Unfortunately, I was unable to activate any purified samples. After 
working on this project for some time, I have come to the conclusion that we need protein 
purification expertise. I recommend actively seeking a post-doctoral researcher with 
experience setting up a recombinant protein, ideally protease, production and purification 
system.  
 The current setup in the lab, with adherent cells grown on cell culture plates or 
flasks, is time consuming, wasteful of reagents and extremely low throughput. Attempts at 
purification and activation consumed massive numbers of cells, due to poor tolerance for 
serum-free media in HEK293Ts. If we ever hope to produce large amounts of cathepsins 
in-house, we need to invest in higher throughput culturing equipment, such as shake flasks 
and convert to suspended cells, either re-deriving the cathepsin mutant lines or using 
transient DNA transfection, which can be very effective when done at scale [136]. 
 I believe a significant factor in our inability to activate purified samples was 
working with insufficient amounts of protein. Due to our cell culture setup, it took multiple 
150mm plates of confluent cells and multiple days to even attempt a single activation 
protocol. Also based on the effectiveness of activation in RAW macrophage media, I 
suspect a greater abundance of cathepsins in our HEK media would make it much easier to 
activate due to the exponential nature of cathepsin activation, where activated cathepsins 
help cleave the propeptides of other procathepsins. 
8.2.5 Cathepsin inhibitors in breast cancer and macrophages 
 Discovering that E64 bound cathepsins can be detectable by cathepsin zymography 
was a significant step toward understanding the complicated nature of cathepsin inhibitors 
in intracellular environments, but there are still many unanswered questions holding back 
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the use of cathepsin inhibitors to prevent cancer metastasis and treat other pathologies 
without incurring unexpected side effects. Experiments with cell lysate and recombinant 
enzymes suggest cathepsins K, L and S retain some zymography detectable activity after 
E64 treatment despite E64’s characterization as an irreversibly binding inhibitor. This is 
consistent with MDA-MB-231cathepsin S retaining zymography detectable signal, but 
cathepsin L from the same cells loses its activity following E64 treatment. The 
conservation of this effect observed in Thp-1 macrophages suggests cathepsin L’s loss of 
activity is tied to fundamental properties of the enzyme rather than a quirk of MDA-MB-
231cells. The exact differences between cathepsins L and S that give rise to this variable 
response to E64 are still open questions. 
 A potential player in the unexpected active cathepsins seen in E64 treated cells is 
the lysosomal protease cathepsin B. Cathepsin B has been shown to prevent transcriptional 
factor EB (TFEB) activation through cleavage of the lysosomal channel protein transient 
receptor potential cation channel, mucolipin subfamily (TRPML1) in macrophages [92]. 
Loss of cathepsin B results in activation of TFEB, a transcription factor which promotes 
lysosomal biogenesis and autophagy through the production of lysosomal hydrolases and 
membrane proteins. E64 is a broad-spectrum cysteine protease inhibitor capable of 
inhibiting cathepsin B similarly to cathepsins L and S. Unpublished results from our lab 
have indicated E64 treatment affects lysosomal distribution in MDA-MB-231cells, likely 
through a similar mechanism to the cathepsin B mediated TRPML1 cleavage in 
macrophages. Probing the system with specific cathepsin L, S and B inhibitors would help 
elucidate the regulatory mechanisms each of the enzymes could be playing in this system.  
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 Cathepsin L largely colocalizes with cystatin B in MDA-MB-231cells, suggesting 
the cathepsin L is in the cytoplasm [50]. Cathepsins in the cytoplasm of cells has been 
shown to induce apoptosis through cleavage of Bid and antiapoptotic proteins in multiple 
cell types [137, 138]. Despite high cytoplasmic concentrations of cathepsin L, MDA-MB-
231cells do not undergo apoptosis, suggesting they have bypassed a conserved apoptosis 
trigger seen in a variety of cancer and non-cancer cell types. This motivates three lines of 
questioning: 1) Why are MDA-MB-231cells seemingly impervious to cytoplasmic 
cathepsin induced apoptosis? 2) Are other cancer cells resistant to cytoplasmic cathepsin 
induced apoptosis? 3) How can this mechanism be exploited or overcome to improve 
cancer treatment? 
 Since cytoplasmic cathepsins induce apoptosis through cleavage of substrates, it is 
possible MDAs evade apoptosis through the inhibition or inactivation of cathepsin L in the 
cytoplasm. A likely candidate for inhibiting cathepsin L is cystatin B, which has been 
shown to colocalize with cathepsin L in these cells. Silencing cystatin B and monitoring 
apoptosis could reveal if this inhibitor is keeping cytoplasmic cathepsin L in check. 
Alternatively, cathepsin L could be overexpressed with DNA or mRNA, potentially 
upsetting the balance between protease and inhibitor that is preventing apoptosis.  
 Whether a tolerance for cytoplasmic cathepsin L is unique to MDA-MB-231 breast 
cancer cells is a relatively easy question to answer, requiring immunocytochemistry or cell 
fractionation combined with protein assays to confirm. While the methodology to answer 
this question is trivial, the implications of multiple cancer cell types evading cathepsin 
induced apoptosis could open up a new line of attack for cancer therapy. 
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 Identifying the exact mechanism responsible for cancer cells evading apoptosis by 
cytoplasmic cathepsins could allow its exploitation for cancer treatment. Assuming 
intracellular cathepsin inhibitors like cystatin B are responsible, these cathepsin inhibitors 
could paradoxically be viable therapeutic targets. A cytoplasmically-targeted small 
molecule cathepsin inhibitor-inhibitor would compete with cathepsins binding cystatin B, 
potentially freeing cytoplasmic cathepsins to induce apoptosis through cleavage of anti-
apoptotic proteins. A cathepsin inhibitor-inhibitor would have the potential to provoke 
unintended extracellular proteolysis or induce apoptosis or lysosomal dysfunction in off-
target cells, but it is an intriguing potential treatment option since most non-cancerous cells 
do not have significant cytoplasmic cathepsins. Even if this theoretical molecule has 
minimal use as a human cancer therapeutic it could still be incredibly useful for proteolytic 
research, since it could be used to disable ubiquitous intra and extracellular cathepsin 
inhibitors, which obfuscate cathepsin dynamics in a variety of tissues. Additionally, 
conjugating the cathepsin inhibitor-inhibitor with a fluorophore would allow for 
monitoring of endogenous cathepsin inhibitor levels inside cells and in extracellular fluids 
in a potentially noninvasive way. 
 Our lab frequently cites the successes and failures of cathepsin inhibitors to treat 
various pathologies as motivation for our work in unraveling proteolytic regulatory 
networks. While I believe this approach is valid, I have often wondered if we could increase 
our impact on future cathepsin inhibitor treatments by studying the side effects of these 
inhibitors more directly. Skin lesions are among the most common side effects of cathepsin 
K inhibitors and dermal fibroblasts express cathepsin K, primarily in their lysosomes to 
facilitate the degradation of endocytosed collagen fragments [43, 139]. Coincidentally, 
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cancer associated fibroblasts are increasingly recognized as important drivers of cancer 
growth and metastasis and have also been shown to produce cathepsins [140]. I think we 
could provide some valuable insight to the pharmaceutical industry by extending the 
cathepsin inhibitor treatment experiments we have previously done in macrophages and 
breast cancer, and expand it to a cell type that is likely instrumental in producing some of 
the side effects that have kept cathepsin inhibitors out of the clinic. 




A.1. Breast cancer inhibitor computational model full details and parameter 
optimization methods. 
 Based on the model diagram in Figure 7-4, we derived a system of ordinary 
differential equations (ODE) using simple mass action (Eqs. 1 – 5) that describe cathepsin 
dynamics. This system of equations contains five dynamic variables corresponding to the 
four cathepsin species and E64, as well as, nine kinetic parameters describing the fluxes 
within the system. Based on our zymography and Western blot data we aimed to identify 
values of the kinetic parameters that are in agreement with our experimental findings.  
 d[Pro]




𝑑𝑡 = kdef ⋅




𝑑𝑡 = khidef ⋅
[Mat] − kcjkr ⋅ [Mathidef] (3) 
 d[MatE64]
𝑑𝑡 = klmn ⋅
[Mat] ⋅ [E64] − kcjklmn ⋅ [MatE64] (4) 
 d[E64]
𝑑𝑡 = khi,lmn − kbtf,lmn ⋅
[E64] − klmn ⋅ [Mat] ⋅ [E64] (5) 
 Parameterization of the dynamic model was performed using a steady state 
approach. We assume that the E64 concentration in the lysosomal compartment, which is 
where cathepsin S is localized, reaches a steady state concentration equal to the specified 
media concentration after 24 hours. Steady state concentrations in the cytosol, which is 
where cathepsin L is localized, were scaled based on an approximation that the cytosol 
volume is 35 times larger than the lysosomal volume. Based on these assumptions, and the 
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proposed system of ODEs (Eqs. 1 – 5), steady state equations were formulated for the three 
tested concentrations of E64: 0 µM, Eqs. 6 – 8; 10 µM, Eqs. 9 – 12; 50 µM, Eqs. 13 – 16. 
This system of equations includes seven unknown steady state kinetic parameters, as well 
as steady state concentrations of cathepsin species that are not directly measurable based 
on available experimental data, including inactive and inhibitor bound cathepsins.  
 
 k`abc − kdef ⋅ [Pro]{|: = 0 (6) 
 kdef ⋅ [Pro]{|: − khidef ⋅ [Mat]{|: − kcjk ⋅ [Mat]{|: = 0 (7) 
 khidef ⋅ [Mat]{|: − kcjkr ⋅ [Mathidef]{|: = 0 (8) 
 k`abc − kdef ⋅ [Pro]z{|: = 0 (9) 
 
kdef ⋅ [Pro]z{|: − khidef ⋅ [Mat]z{|: − kcjk ⋅ [Mat]z{|:
− klmn ⋅ [Mat]z{|: ⋅ [E64]z{|: = 0 
(10) 
 khidef ⋅ [Mat]z{|: − kcjkr ⋅ [Mathidef]z{|: = 0 (11) 
 klmn ⋅ [Mat]z{|: ⋅ [E64]z{|: − kcjklmn ⋅ [MatE64]z{|: = 0 (12) 
 k`abc − kdef ⋅ [Pro]{|: = 0 (13) 
 
kdef ⋅ [Pro]{|: − khidef ⋅ [Mat]{|: − kcjk ⋅ [Mat]{|:
− klmn ⋅ [Mat]{|: ⋅ [E64]{|: = 0 
(14) 
 khidef ⋅ [Mat]{|: − kcjkr ⋅ [Mathidef]{|: = 0 (15) 
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 klmn ⋅ [Mat]{|: ⋅ [E64]{|: − kcjklmn ⋅ [MatE64]{|: = 0 (16) 
 Eqs. 17 – 22 relate the Western blot and zymography measurements for the 
specified E64 concentration to the corresponding steady state concentrations of the 
different species of mature cathepsin. Procathepsin concentrations are absent from these 
equations, since steady concentrations were determined by the procathepsin bands of the 
corresponding Western blots. At 0 µM of E64, the mature cathepsin species are computable 
directly from the Western blot and zymography, while at 10 and 50 µM of E64 the steady 
state model is required to determine the steady state concentrations of some mature 
cathepsin species.    
 𝑊𝐵{|: = [Mat]{|: + [Mathidef]{|: (17) 
 𝑍𝑦𝑚𝑜{|: = [Mat]{|: (18) 
 𝑊𝐵z{|: = [Mat]z{|: + [Mathidef]z{|: + [MatE64]z{|: (19) 
 𝑍𝑦𝑚𝑜z{|: = [Mat]z{|: (20) 
 𝑊𝐵{|: = [Mat]{|: + [Mathidef]{|: + [MatE64]{|: (21) 
 𝑍𝑦𝑚𝑜{|: = [Mat]{|: (22) 
 The steady state equations (Eqs. 6 – 16) can be simplified based on the expressions 
relating the experimental measurements with the steady state cathepsin concentrations 
(Eqs. 17 – 22). Eqs. 23 – 28 define the steady state concentrations of mature cathepsin 
species at 10 and 50 µM of E64 in terms of experimental measurements and the kinetic 
parameters.  
 [Mat]z{|: = 𝑍𝑦𝑚𝑜z{|: (23) 
 127 








 [Mat]{|: = 𝑍𝑦𝑚𝑜{|: (26) 











 By using the expressions in equations Eqs. 23 – 28, the steady state equations (Eqs. 
6 – 16) were reduced to a system of six equations (Eqs. 29 – 34) with six cathepsin-related 
kinetic parameters as unknowns, while the cathepsin production rate can later be 
determined based on Eq. 6. Eqs. 29 – 32 define the relationship between the kinetic 
parameters and the steady state concentrations, while Eqs. 33 and 34 serve as constraints 
connecting the steady state concentrations to the experimental data. Additionally, the 
observation that procathepsin concentrations were not significantly affected by E64 
concentration was used to simplify the model further.  
 [Mat]z{|: − [Pro]{|: ⋅
𝑘;H&
𝑘}B;H& + 𝑘!~ + 𝑘mn ⋅ [E64]z{|:
= 0 (29) 
 [Mat]{|: − [Pro]{|: ⋅
𝑘;H&
𝑘}B;H& + 𝑘!~ + 𝑘mn ⋅ [E64]{|:
= 0 (30) 
 kdef ⋅ [Pro]{|: − [Mat]{|: ⋅ khidef + kcjk = 0 (31) 
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 khidef ⋅ [Mat]{|: − kcjkr ⋅ [Mathidef]{|: = 0 (32) 
 [Mat]z{|: + [Mathidef]z{|: + [MatE64]z{|: −𝑊𝐵z{|: = 0 (33) 
 [Mat]{|: + [Mathidef]{|: + [MatE64]{|: −𝑊𝐵{|: = 0 (34) 
 Parameter estimation was initially performed for cathepsin S and L based on the 
Eqs. 23 – 34, where the squared residuals for Eqs. 29 – 34 were minimized with respect to 
the six kinetic parameters. These equations define a nonlinear root finding problem 
composed of six equations and six unknowns, where an exact solution cannot be 
determined analytically. Therefore, a numerical approximate solution was obtained using 
a newly developed optimization algorithm for black-box problems by identifying kinetic 
parameter values that minimized the sum of the squared residuals for Eqs. 29 – 34. Based 
on this model, parameter estimation for cathepsin L proved successful with the 
identification of a solution with low residuals, but for the case of cathepsin S no reasonable 
solution was found.  
 Further analysis lead to redefining the relationship between the zymography 
measurements and steady state cathepsin concentrations, specifically mature cathepsin S 
bound to E64 was found to be detectable by zymography. Therefore, for cathepsin S the 
relationships in Eqs. 20 and 22 were replaced with Eqs. 35 and 36.  
 𝑍𝑦𝑚𝑜z{|: = [Mat]z{|: + [MatE64]z{|: (35) 
 𝑍𝑦𝑚𝑜{|: = [Mat]{|: + [MatE64]{|: (36) 
 With Eqs. 35 and 36 the simplification of the steady state parameters is no longer 
possible, therefore the cathepsin S parameters were identified using the full set of steady 
state equations, including Eqs. 6 – 19, 21, 35, and 36. Based on these equations, a similar 
optimization approach using the black-box optimization algorithm was used to determine 
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the steady state kinetic parameters. For the updated cathepsin S model, there are 13 
unknowns including seven kinetic parameters and six steady state concentrations for 
mature cathepsin S species. The parameter estimation was performed by minimizing the 
squared residuals for Eqs. 6 – 19, 21, 35, and 36 with respect to all 13 unknowns, but the 
final steady state concentrations for cathepsin S species were back calculated based on the 
steady state kinetic parameters.  
 Dynamic simulations were performed based on the steady state kinetic parameters 
and the system of ODEs defined by Eqs. 1 – 5. The rate of influx and efflux for E64 were 
approximated to ensure that the assumed steady state E64 concentrations were reached 
within 24 hours. Additionally, the kinetic parameters were scaled to ensure the system 
reached a steady state within 24 hrs. Numerical simulations were performed using the 
deSolve package in the R statistical language.  
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A.2. Cathepsin S and K overexpression model parameter estimation details 
 A total of 12 model parameters were estimated using COPASI’s built-in genetic 
algorithm implemented on Georgia Tech’s Partnership for an Advanced Computing 
Environment (PACE) Cluster. The genetic algorithm was implemented 100 times, with 
randomized initial conditions, population of 10,000 and run for 200 generations, resulting 
in approximately 2x106 function evaluations per run. Default COPASI genetic algorithm 
settings were used (Log verbosity = 0, Random number generator = 1, Seed = 0, Mutation 
variance = 0.1). Parameter space was bounded as indicated in Table A.2-1. Upper bounds 
for reaction on rates were restricted to below the measured binding rate of streptavidin on 
biotin, one of the strongest naturally occurring, non-covalent molecular interactions 
currently known [141]. Bounds for reaction off rates and catalytic rates were set based on 
experimentally measured extremes of these rates previously documented in different 
enzymes [142]. Secretion rates were initially allowed to vary between 1x10-6 and 1x106, 
but repeated runs consistently estimated the secretion rates to fall between 1 and 200. 
General degradation rates were initially bounded between 1x10-6 and 1x106, but solutions 
with high general degradation rates had very little impact of cathepsins on cathepsin 
degradation, which does not agree with the experimental data. Degradation rates were 











Table A.2 -  1: Lower and upper bounds for parameter estimation 
Parameter Lower Bound Upper Bound 
Ssec 1 200 
Sact 1x10-6 1x106 
Sdeg 1x10-6 10 
Ksec 1 200 
Kact 1x10-6 1x106 
Kdeg 1x10-6 10 
SonK 1x10-6 3.6 
SoffK 1x10-4 1x106 
ScatK 1x10-2 1x107 
KonK 1x10-6 3.6 
KoffK 1x10-4 1x106 




A.3. Identification of Critical Quality Attributes in Mesenchymal Stem Cells 
A.3.1. Introduction 
 Georgia Tech, University of Wisconsin-Madison, University of Georgia and 
University of Puerto Rico Mayaguez and other academic and industry partners have been 
awarded a National Science Foundation Engineering Research Center for the purpose of 
developing Cell Manufacturing Technologies (CMaT). The goal of the center is to “enable 
robust, scalable, low-cost biomanufacturing of high-quality therapeutic cells to bring 
affordable, curative therapies against incurable chronic diseases”. Cell culture conditions 
are a key component of cell manufacturing and identifying non-invasive indicators of 
optimal cell culture conditions and high-quality cells will be instrumental to increasing cell 
manufacturing output while keeping quality high and lowering costs. A major initiative of 
CMaT is identifying critical quality attributes (CQAs), capable of being monitored non-
invasively during cell manufacture, for the production of Chimeric Antigen Receptor 
(CAR) T cells for cancer immunotherapy, induced pluripotent stem cells (iPSC) 
cardiomyocytes for cardiac regeneration and mesenchymal stem cells (MSCs) for immune 
modulation and musculoskeletal repair. Once CQAs have been identified, robust cell 
manufacturing processes can be designed, capable of monitoring cell quality at multiple 
stages during development. 
 This appendix focuses on identifying indicators of poor cell culture conditions in 
MSCs. MSCs are multipotent progenitor cells found in bone marrow, adipose tissue, 
amniotic membranes and umbilical cords capable of differentiating into osteoblasts, 
adipocytes and chondrocytes [143]. MSCs derived from adult bone marrow are currently 
the most popular tissue source [144]. MSCs, particularly those isolated from adult bone 
marrow, display significant inter-donor variability in gene expression, morphology and 
cytokine secretion [143, 145]. Due to this high degree of donor variability, this pilot study 
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was conducted to identify cytokines secreted by CMaT MSCs and observe the effects of 
suboptimal cell culture conditions on the MSC secretory profiles. 
 
 
Figure A.3 - 1: Experimental design to identify indicators of poor cell culture conditions in 
mesenchymal stem cells (MSCs).  
MSCs were grown in media supplemented with 10% fetal bovine serum or in media 
containing no fetal bovine serum for 48 hours. Conditioned media, exosomes and cell 
extracts were then analyzed for proteins and metabolites by multiple research groups using 
Luminex (detailed here), Nuclear Magnetic Resonance, Cluster Designation and Liquid 
Chromatography Mass Spectrometry. Data collected from these techniques will then be 
used to develop a multivariable model capable of identifying critical quality attributes for 
industrial MSC culture. 
A.3.2. Materials and Methods 
A.3.2.1. Mesenchymal Stem Cell Culture 
 Mesenchymal stem cells, induced from pluripotent stem cells (Cellular Dynamics 
lot 0003) were plated in 150mm plates at a density of 500 cells/cm2 and cultured at 37°C 
and 5% CO2 in MEM-⍺ media (Gibco) supplemented with 1% L-Glutamine 200mM 
(Gibco), 1% Penicillin Streptomycin (Gibco) and with or without 10% Fetal Bovine Serum 
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(Hyclone). Cells were passaged upon reaching 80% confluency. Media was collected after 
48 hours of culture in complete or serum-free media. 
A.3.2.2. Human Luminex Performance Assay 
 Human magnetic Luminex performance assay kit and a customized panel of 
cytokine microparticles were purchased from R&D Systems and assay was carried out 
according to the manufacturer’s instructions. Briefly, conditioned media samples, either 
complete or serum-free, were incubated with microparticles for 3 hours. Biotin conjugated 
antibodies were added to the microparticles and incubated for 1 hour, followed by 
Streptavidin-PE and another 30 minutes of incubation. Fluorescence of the microparticles 
was measured in a Bio-Rad Bio-Plex 200 System. All incubations were done at room 
temperature on a shaker at 800 rpm. All wash steps were done using a magnetic plate. 
 
Table A.3 -  1: Cytokines profiled in MSC conditioned media 
 
Analyte Function 
CCL2 Recruits immune cells to sites of inflammation 
Angiopoeitin-1 Promote angiogenesis and vascular growth 
IL-6 Numerous, pro-inflammatory signaling 
Cystatin C Inhibitor of cysteine cathepsin proteases 
IL-8/CXCL8 Stimulates neutrophil migration and phagocytosis 
VEGF Encourages formation of blood vessels,  
TNF-alpha Regulates immune cells and systemic inflammation 
CCL3/MIP-1alpha Recruits and activates granulocytes to sites of inflammation 
FGF basic Numerous, cell growth and development, embryonic development 
G-CSF Stimulates granulocyte and stem cell production and release 
Eotaxin Recruits and activates Eosinophils to sites of inflammation 
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EGF Promotes cellular proliferation, differentiation and survival 
 
A.3.3. Results 
 Mesenchymal stem cells were cultured with complete media (containing fetal 
bovine serum) or in serum-free media for 48 hours, after which cell extracts, conditioned 
media and media exosomes were collected for analysis with a variety of analytical methods 
(Figure A.3-1). Conditioned media and cell-free media controls were probed for 12 
different cytokines, which have previously been identified in MSC media (Table A.3-1).  
 Out of the 12 cytokines measured, 10 were detectable in media samples and 6 were 
significantly different between MSC conditioned complete and serum-free media (Figure 
A.3-2). CCL2/MCP-1, Angiopoietin-1, IL-6, Cystatin C and IL-8/CXCL8 were 
significantly lower in serum-free than complete media, while VEGF was significantly 
higher in serum-free media than complete media. TNFα, CCL3/MIP-1α, FGF-Basic and 
G-CSF were not significantly different between the MSC complete and serum-free 
conditions. Most of the cytokines measured were nearly undetectable in cell-free media 
controls, indicating the cytokines are produced by the MSCs and not found in fetal bovine 
serum, with the exception of angiopoietin-1. 
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Figure A.3 - 2: Serum affects cytokines found in MSC media.  
CCL2/MCP-1, Angiopoietin-1, IL-6, Cystatin C, IL-8/CXCL8 were found in significantly 
greater concentrations in conditioned complete media than serum-free media. VEGF was 
significantly greater in serum-free than complete media. TNF-alpha, CCL3/MIP-1alpha, 
FGF basic and G-CSF were not different between complete and serum-free media. 
Angiopoietin-1 and VEGF were detectable in small amounts in cell-free complete media, 
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but no other analytes were found in cell-free media. Eotaxin and EGF were also measured, 
but were undetectable in any samples. n=3 *p<0.05 by t-test. 
 
A.3.4. Discussion 
 This study provides proof of concept that cytokine measurements can be used to 
differentiate between mesenchymal stem cells grown under different culturing conditions. 
Cytokine profiling of mesenchymal stem cell media is a non-invasive method of 
monitoring cell health that could be implemented in larger scale manufacturing processes 
to continuously measure the quality of new cells.  
 The Luminex results show a variety of cytokines are detectable in MSC media and 
that many of them are responsive to media serum content. Importantly, most of the 
cytokines were extremely rare in cell-free media, indicating these cytokines are being 
produced by the MSCs and not supplied by the media or serum. Several of the cytokines 
that were lower in serum-free media function primarily to recruit immune cells 
(CCL2/MCP-1, IL-6, IL-8/CXCL8) indicating loss of serum could interfere with immune 
cell recruitment by MSCs. Interestingly, we observed opposite responses in two angiogenic 
proteins with Angiopoietin-1 being lower in serum-free media while VEGF was increased 
in serum-free media, indicating serum affecting blood vessel growth in a complicated 
manner. Cystatin C, the endogenous protein inhibitor of cysteine cathepsins secreted 
constitutively by most human cell types, was almost undetectable in MSC serum-free 
media. Transcripts of multiple cystatins, including cystatin C, are significantly lower in 
human fetal liver derived MSCs compared to human adult bone marrow derived MSCs, 
showing cystatin C secretion varies among different MSC sources [146]. Secretion of 
cystatin C decreases upon differentiation of human bone marrow derived MSCs to 
osteoblasts, suggesting cystatin C could be a useful biomarker for MSC potency [147].  
 This data can also be used to construct multivariable partial least square regression 
models capable of predicting cell health and cell culture conditions based on the secreted 
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cytokine profile detectable in cell culture media. Future studies will examine the 
differences in cytokine secretomes of MSCs from different sources, including bone marrow 
and induced pluripotent stem cell derived MSCs. Identifying cytokines with conserved 
responses to cell culture conditions across different MSC lineages will ensure model 
predictions are robust and applicable to the many sources of MSCs currently under 
investigation for therapeutic applications. 
A.4. Aggressive Breast Cancer in Ethiopian Women 
A.4.1. Introduction 
 In the United States, median age of breast cancer diagnosis is 63 years for white 
women and 59 years for black women, and about half of breast cancer is diagnosed while 
still localized at the primary site [116]. At Black Lion Hospital in Addis Ababa, Ethiopia 
(one of the largest hospitals in the country) the median age of breast cancer diagnosis is 40 
years and a majority of cases have already metastasized out of the primary tumor site by 
time of diagnosis. Through our collaboration with the researchers at Black Lion Hospital 
and Addis Ababa University, we hope to assist in the discovery of the mechanisms 
responsible for this extremely aggressive cancer seen in Ethiopian women. One potential 
hypothesis we are exploring is upregulation of active proteases, including cysteine 
cathepsins, in aggressive breast cancer. We also investigated the abundance of the 
inflammatory cytokines TNFα and IL-6, as well as cystatin C, in plasma from patients 
undergoing chemotherapy at Black Lion Hospital. 
A.4.2. Materials and Methods 
A.4.2.1. Preparation of human samples 
 Primary tumor and patient-matched non tumor mammary tissue were collected 
from six patients during mastectomy and frozen. Samples were homogenized by grinding 
in a mortar and pestle with zymography lysis buffer. Whole blood from 26 patients before 
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and after chemotherapy was collected in heparinized tubes, centrifuged to remove red and 
white blood cells and frozen. 
A.4.2.2. Cathepsin zymography 
 Protein concentration of homogenized samples were determined by BCA and equal 
amounts of protein were analyzed by cathepsin zymography as previously described [84, 
85]. 
A.4.2.3. Human Luminex Performance Assay 
 Human magnetic Luminex performance assay kit and a customized panel of 
cytokine microparticles were purchased from R&D Systems and assay was carried out 
according to the manufacturer’s instructions. Briefly, equal volumes of patient serum were 
incubated with microparticles for the analytes of interest. Biotin conjugated antibodies 
were added to the microparticles and incubated for 1 hour, followed by Streptavidin-PE 
and another 30 minutes of incubation. Fluorescence of the microparticles was measured in 
a Bio-Rad Bio-Plex 200 System. All incubations were done at room temperature on a 
shaker at 800 rpm. All wash steps were done using a magnetic plate. 
A.4.3. Results 
A.4.3.1. Active cathepsins overexpressed in Ethiopian breast cancer tissue samples 
Equal amounts of homogenized primary cancer (C) and patient-matched normal tissue (N) 
from six patients were loaded and analyzed by cathepsin zymography. Active cathepsins 
were clearly detectable in cancer tissue from most of the patients, primary a 20 kDa band 
consistent with active cathepsin L. An approximately 35 kDa band was also detectable in 
cancer tissue from one patient, potentially caused by cathepsin S or cathepsin V. These 
results support the hypothesis that active cathepsins are involved in Ethiopian breast 
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cancer. Additional experiments will be required to compare the relative active proteases in 
samples from Ethiopian patients to other patient groups. 
 
 
Figure A.4 - 1: Active cathepsins are elevated in breast cancer tissue compared to patient-
matched controls.  
Cancer (C) and normal (N) tissue from six Ethiopian breast cancer patients was 
homogenized in a mortar and pestle and equal amounts of protein were loaded for cathepsin 
zymography. Active cathepsin L was stronger in the cancer than normal tissue and active 
cathepsin S was detectable in one cancer sample and none of the normal samples. 
 
A.4.3.2. Cytokine expression in Ethiopian breast cancer patient plasma  
 Levels of TNFα, IL-6 and cystatin C in serum from Ethiopian breast cancer patients 
undergoing chemotherapy at Black Lion Hospital were measured by Luminex. The average 
values of each cytokine are reported in Table A.4-1. No statistically significant differences 
in cytokine expression were observed following chemotherapy. Cystatin C expression was 
found to be approximately 100,000-fold higher than TNFα or IL-6 levels. 
 
Table A.4-1: Average cytokine levels in plasma from Ethiopian breast cancer patients 
(pg/mL) Pre-Chemotherapy Post-Chemotherapy 
TNFα 4.2 ± 2.3 4.7 ± 1.8 
IL-6 6.4 ± 11.4 2.9 ± 4.3 
Cystatin C 283962.1 ± 143066.8 310618.7 ± 133230.8 
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 When cytokine levels in individual patients were compared pre and post 
chemotherapy, a significant increase in TNFα was observed, while IL-6 and Cystatin C 
were not significantly different (Figure A.3-2A&B). The majority of patients had 
extremely low or undetectable levels of IL-6 (Figure A.3-2A). However, among patients 
with initial IL-6 levels above 10 pg/mL, IL-6 was significantly decreased following 
chemotherapy. Cystatin C levels were not significantly different before and after 
chemotherapy, but there was some variability in cystatin C levels among the patients, 
ranging from 57,000 to 880,000 pg/mL with most samples falling close to the mean value 
of 280,000 pg/mL. 
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Figure A.4 - 2: Plasma TNFα increases and IL-6 decreases in Ethiopian breast cancer 
patients following chemotherapy.  
Plasma TNFα, IL-6 and cystatin C levels before and after chemotherapy were measured 
using a multiplex magnetic bead Luminex assay and displayed in a heat map, where darker 
colors indicate a higher relative amount of the target protein in the plasma samples (A). 
Plasma TNFα increased following chemotherapy in most of the subjects (n=26 p=0.0014 
by matched pairs t-test). Each line represents a patient, green lines have a positive slope, 
indicating an increase in TNFα while red lines have a negative slope, indicating a decrease 
(B). IL-6 was undetectable in most of the patient samples, but among patients with high 
initial plasma IL-6, IL-6 decreased following chemotherapy shown in a heat map (C) and 
line plot (D) (n=6 p=0.044 by matched pairs t-test). 
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 Active cathepsins were elevated in primary tumors compared to patient matched 
normal tissue. This supports the hypothesis that active cathepsins play a role in breast 
cancer in Ethiopian women. Levels of TNFα, IL-6 and cystatin C in the plasma of Ethiopian 
cancer patients were quantified before and after chemotherapy. TNFα levels were found to 
decrease post-chemotherapy in a statistically significant number of patients, and IL-6 levels 
were found to significantly increase post-chemotherapy among patients with high initial 
IL-6 levels. 
 The TNFα levels we observed in the samples from Ethiopian patients was higher 
than previously reported in a study of 40 Taiwanese women with breast cancer, which 
measured an average of 1.47 pg/mL by ELISA compared to our averages of 4.2 and 4.7 
pg/mL before and after chemotherapy [148]. The IL-6 levels measured here are lower than 
those previously reported in studies of breast cancer in Egyptian women, which detected 
an average of 111.38pg/mL across 40 patients, compared to our averages of 11.4 and 4.3 
pg/mL before and after chemotherapy [149]. These results suggest some possible avenues 
of future research to hopefully identify the causes of this aggressive cancer observed in 




A.5. CM Papain and concentration methods effects on cathepsin cannibalism 
 
Figure A.5 - 1: Cathepsin K levels are higher in acetone precipitated media from 
macrophages than in centrifugally concentrated media from HEK293T cells.  
Cathepsin and cystatin C levels in concentrated conditioned media from different 
cocultures were assed by Western blot. Procathepsin K levels were higher in the Thp-1 
macrophage cocultures than the HEK293T only cocultures. Cathepsin S levels were similar 
between the cocultures. Cystatin C levels were slightly higher in macrophage cocultures 
than HEK293T cocultures. Thp-1 cocultures were concentrated with acetone precipitation 




































Figure A.5 - 2: Acetone precipitation prevents detection of cannibalism in HEK293T cells 
and CM Papain appears to allow cathepsin K to be degraded.  
HEK293T cells were cocultured with cystatin C mRNA transfection, 50 µM E64 treatment 
or 1 µM carboxymethyl (CM) papain. No CatS on CatK cannibalism was observed in the 
control groups when using acetone precipitation. Cystatin C transfection and E64 treatment 
had no effect on cathepsin K levels. CM papain, a partially deactivated version of papain 
was used to compete for cystatin C in the media. CM papain treatment reduced 
procathepsin K levels and increased mature cathepsin S levels. However, CM papain also 
appeared to be detectable by the cathepsin S antibody used, since a 25 kDa band was 







Figure A.5 - 3: CM Papain lowers cathepsin K and cystatin C levels, while increasing 
mature cathepsin S.  
Macrophage cocultures were transfected with cystatin C mRNA or treated with 50 µM E64 
or 1 µM CM Papain. Cathepsin K levels were higher in macrophage cocultures than 
HEK293 cocultures. CM papain abolished pro- and mature cathepsin K, procathepsin S 
and cystatin C levels. CM papain should not directly interact with cathepsins, but it should 
bind and not degrade cystatin C. These results suggest there is significant residual activity 
in the CM papain, likely caused by incomplete methylation of the enzyme. The CM papain 
appears to have cleaved all of the cystatin C, and potentially could have cleaved cathepsins 










Figure A.5 - 4: CM Papain degrades cathepsins S and K and is detectable by cathepsin S 
antibody.  
100 nM recombinant human cathepsins S and K were incubated in serum-free DMEM for 
1 hour at 37°C  ±10 µM CM papain or normal papain with ±1 mM E64 then analyzed by 
Western blot. CM papain and normal papain were both detected by the cathepsin S 
antibody (polyclonal goat IgG R&D Systems) but not the cathepsin K antibody (Polyclonal 
rabbit IgG Proteintech). CM papain and normal papain degraded pro- and mature cathepsin 
S and mature cathepsin K. Degradation was stopped by incubating the enzymes with E64. 
CM papain and normal papain also appeared to partially auto-degrade during the 
incubation, since the 25 kDa bands on the cathepsin S blot were darker when incubated 
with E64. Cathepsins S and K appear to have slightly auto-degraded during the incubation, 
with E64 treated bands appearing darker than bands for the enzyme incubated alone. Total 
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